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Abstract 
Introduction 
 
Upon entry into the central nervous system different pathogens are recognized by different 
pathogen receptors (e.g. Escherichia coli (E. coli) is recognized by Toll like receptor 4) present 
on the surface of innate immune cells. Once recognized, pathogens activate the innate immune 
system of the host which ultimately results in the synthesis and release of pro-inflammatory 
cytokines (e.g. Interleukin-1β (IL-1β)). Pro-inflammatory cytokines are the primary mediators of 
the acute phase response which consists of a suite of physiological and behavioural changes 
which include fever, lethargy, anorexia and in some cases memory impairment. Clinical cases of 
central bacterial infections (e.g. meningitis and brain abscesses) have shown that in addition to 
developing fever, lethargy and anorexia, one third of patients also present with cognitive deficits.  
Laboratory based studies simulating central bacterial infections using Lipopolysaccharide (LPS), 
the active fragment of E. coli, and IL-1β have well documented their effects on fever, anorexia, 
and lethargy. In addition centrally administered IL-1β has also been demonstrated to effect on 
memory, however no studies have examined the effect of centrally administered LPS on 
memory. Furthermore, to my knowledge, no studies have concurrently examined the impact of a 
simulated central bacterial infection using LPS or IL-1β on a suite of sickness responses 
including body temperature, activity, food intake, body mass and memory. Therefore I set out to 
concurrently examine body temperature, voluntary activity, food  intake, body mass and memory 
after the central administration of either LPS or IL-1β and their appropriate vehicles.  
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Materials and methods 
 
Male Sprague-Dawley rats (~200g) were anaesthetised and had radiotelemeters implanted intra-
abdominally, which measured abdominal temperature and cage activity. Body mass and food 
intake were measured daily. The contextual and auditory fear conditioning paradigm was used to 
assess memory in rats. Fear conditioning entails conditioning/training of rats and performing two 
memory (hippocampal and amygdala dependent) tests. Rats were randomly assigned to receive a 
single intra-cisterna magna (ICM) injection of either LPS (10 µg or 100 µg), IL-1β (100 ng) or 
vehicle (phosphate buffered saline or 0.1% bovine serum albumin) in a total volume of 5 µl. Rats 
set to receive LPS and PBS were assigned to a protocol in which they were conditioned/trained, 
followed by an immediate ICM injection of either LPS or PBS. Rats set to receive IL-1β or BSA 
were assigned to one of two protocols: a) a protocol in which rats were conditioned/trained, 
followed by an immediate ICM injection of either IL-1β or BSA; b) a protocol in which rats first 
received an ICM injection of either IL-1β or BSA and then were conditioned/trained 2 h later. 
Sickness responses were measured for 7 days following injection and memory was assessed on 
day 7. In addition, hypothalamic and hippocampal concentrations of IL-1β for rats that received 
IL-1β and BSA were measured at several time points following injection.  
Results 
 
Following the administration of LPS, rats showed a dose-dependent hypothermia which preceded 
a fever, as well as a dose-dependent decrease in nocturnal activity, food intake and body mass (P 
< 0.05). However, regardless of dose, LPS administered immediately after conditioning had no 
effect on hippocampal-dependent memory assessed 7 days after LPS administration (P > 0.05). 
Moreover, following IL-1β administration, rats showed an increase in body temperature, a 
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decrease in activity and food intake and had significantly increased concentrations of IL-1β in 
the hippocampus and hypothalamus (P < 0.05). Furthermore, rats that received IL-1β 
immediately after conditioning had no effect on hippocampal-dependent memory (P > 0.05) 
however, rats that received IL-1β 2 h before being conditioned showed both hippocampal and 
amygdala-dependent memory impairment (P < 0.05).  
Discussion and conclusion 
 
The results of the present study suggest that a central infection severe enough to induce a suite of 
sickness responses including fever, anorexia and lethargy may occur without incurring memory 
impairment in rats. However, rats that received IL-1β 2 h before being conditioned were 
conditioned at a time when brain IL-1β concentrations were raised and whilst  they were febrile,  
which suggests that memory impairment may occur, concurrently with other sickness 
behaviours, only when learning takes place during an immune  challenge within the brain. 
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1.1. Central nervous system infections 
 
The brain and central nervous system are considered to be sterile areas of the body not normally 
inhabited by pathogens (Agyeman et al., 2014). The brain’s innate protective barriers which 
include the blood brain barrier and the skull, protect the brain to a large extent from infection and 
inflammation (Agyeman et al., 2014). However, central infections such as brain abscesses and 
bacterial meningitis can occur with potentially fatal consequences.  
Upon entry into the central nervous system pathogens are detected by means of pathogen-
associated molecular patterns (PAMPs) (Kapetanovic and Cavaillon, 2007, Kelley et al., 2003). 
A PAMP is a specific, structurally conserved molecule, unique to the pathogen that enables its 
recognition by the innate immune system of the infected host (Heumann and Roger, 2002, 
Kapetanovic and Cavaillon, 2007, Kelley et al., 2003). The detection of PAMPs in the brain is 
mediated by pattern-recognition receptors, including transmembrane proteins known as Toll–like 
receptors (TLR) (Dantzer, 2009, Heumann and Roger, 2002, Kapetanovic and Cavaillon, 2007).  
Pattern-recognition receptors are expressed on the surface of innate immune cells such as 
microglia, astrocytes, neurons and endothelial cells (Kapetanovic and Cavaillon, 2007).  
Escherichia coli (E. coli) is a Gram-negative bacterium that frequently causes central infections 
(Agyeman et al., 2014). Lipopolysaccharide (LPS) is the active fragment of E. coli and is 
frequently administered experimentally in order to mimic Gram-negative bacterial infections and  
associated inflammation (Conti et al., 2004). Lipid A is the active structural moiety of LPS and it 
is the PAMP that is recognized by host immune cells (Heumann and Roger, 2002). The 
mechanism of LPS recognition in the host begins by the dissociation of LPS into a LPS-binding 
protein (LBP) complex which is then transferred to the functional membrane bound LPS receptor 
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cluster of differentiation 14 (CD14), which leads to early cellular activation (see Figure 1.1) 
(Conti et al., 2004, Heumann and Roger, 2002). There is substantial evidence that LBP is 
specifically detected by Toll-like receptor – 4 (TLR-4) (Heumann and Roger, 2002). Once 
activated, TLR-4 transmits the LPS signal from CD14 to the cytoplasm (Heumann and Roger, 
2002). Signaling from CD14 to the cytoplasm occurs via systematic recruitment of the myeloid 
differentiation factor (MyD88) which results in the activation of transcription factors. The 
transcription factors promote the expression of immune response genes which stimulate the 
release of a suite of pro-inflammatory cytokines, including interleukin (IL)-1α, IL-1β, IL-6, and 
tumor necrosis factor (TNF)-α (Conti et al., 2004, Leon, 2004).  
 
 
LPS
Dissociates to form LPS/LBP 
complex
Bind to CD14 and TLR-4
MyD88
Activation of transcription 
factors
Pro-inflammatory cytokines 
IL-1α, IL-1β, IL-6 and TNF-α
Figure 1.1 - The activation of the pro-inflammatory cascade after the central administration of 
LPS, adapted from Conti et al. (2004). Abbreviations: Lipopolysaccharide (LPS), 
Lipopolysaccharide-binding protein (LBP), Cluster of differentiation 14 (CD14), Toll-like 
receptor – 4 (TLR-4), Myeloid differentiation factor (MyD88), Interleukin-1α (IL-1α), 
Interleukin-1β (IL-1β), Interleukin-6 (IL-6) and Tumor-necrosis factor-α (TNF-α). 
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Pro-inflammatory cytokines are the primary mediators in the implementation of the host acute 
phase response (Dantzer et al., 2008). The acute phase response consists of a suite of 
physiological and behavioural changes (Dantzer, 2009, Pugh et al., 2001), some of which include 
an increase in core body temperature, as well as non-specific, non-thermal behavioural changes 
such as lethargy, anorexia, malaise, depression and in some cases even cognitive deficits (Begg 
et al., 1999, Dantzer, 2009, van de Beek et al., 2002). These changes are collectively referred to 
as sickness responses and are present in both mild and severe infections (Dantzer et al., 2008). 
Generally, sickness responses are not considered to be maladaptive or undesirable, but rather as a 
change in the motivational state of an organism (Dantzer, 2009) that may be critical to fighting 
off an infection (Hart, 1988, Pugh et al., 2001). However, chronic infections and inflammation 
can exacerbate the intensity and duration of sickness responses (Dantzer et al., 2008) which may 
result in devitalisation of the host, a decreased quality of living, organ failure and death (Kelley 
et al., 2003). 
The implementation of sickness responses is also mediated by the action of pro-inflammatory 
cytokines (Dantzer, 2009). Pro-inflammatory cytokines do not work in isolation to implement 
sickness responses, once they have been released they induce the synthesis and secretion of other 
cytokines (Alheim et al., 1997, Cartmell and Mitchell, 2005, Fantuzzi et al., 1996), which have 
been shown to act synergistically and additively (Harden et al., 2008, Pugh et al., 2001, Sonti et 
al., 1996). Although pro-inflammatory cytokines may work synergistically to induce sickness 
responses, the relative potency of individual cytokines has also been assessed in order to 
examine the predominant cytokines involved in mediating centrally-induced sickness responses. 
Cytokine potency has previously been determined by comparing the magnitude of sickness 
responses induced by individual cytokines administered at the same dose (Anforth et al., 1998, 
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Busbridge et al., 1989, Harden et al., 2008). For example, several studies have reported that 
centrally administered IL-1β induces sickness responses (including fever, anorexia, lethargy and 
memory impairment) of a greater magnitude compared to the same dose of centrally 
administered IL-6 and TNF-α, which may indicate that IL-1β is a more potent mediator of the 
sickness responses (Goshen and Yirmiya, 2006, Harden et al., 2008, Sonti et al., 1996).  
IL-1β is a member of the IL-1 family of pro-inflammatory cytokines. IL-1β is synthesized by 
innate immune cells (e.g. microglia, astrocytes and monocytes/macrophages) as a precursor 
protein and becomes biologically active after proteolytic cleaving via IL -1β converting enzyme 
(caspase-1) (Fantuzzi et al., 1996, Zheng et al., 1995). Mature IL-1β is then secreted from the 
innate immune cells in which it was synthesized (Dinarello, 2005; Fantuzzi et al., 1996; Zheng et 
al., 1995) and elicits its biological action through binding to specific IL-1 receptors (Dinarello, 
2005).  There are three IL-1 receptors, interleukin-1 receptor type 1 (IL-1rI), interleukin-1 
receptor type 2 (IL-1rII)  and  interleukin-1 receptor type 3 (IL-1rIII) (Dinarello, 2000, Qian et 
al., 2012), which are widely distributed throughout the brain indicating a broad spectrum of 
action for IL-1β (Farrar et al., 1987, Qian et al., 2012). IL-1r1 is a functional receptor 
responsible for signal transduction and initiation of biological activity for IL-1β (Dinarello, 
2000). Upon interaction with IL-1r1 within the brain, IL-1β triggers a cascade of inflammatory 
events, which includes the release of secondary pro-inflammatory cytokines such as IL-6 and 
TNF-α as well as other pro-inflammatory markers and mediators, including Cyclooxygenase-2 
(COX-2), Nitric oxide (NO) and Prostaglandin (PG) (Dinarello, 2000). IL-1rII is a functionally 
negative decoy receptor which binds IL-1β with a high affinity, inhibiting binding to IL-1rI and 
thus inhibiting agonistic biological activity (Dinarello, 2000). IL-1rIII is a truncated form of IL-
1rI and acts as an accessory receptor to IL-1rI (Boraschi and Tagliabue, 2013, Qian et al., 2012). 
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IL-1rIII does not bind directly to IL-1β, rather it binds to IL-1β-IL-1rI or IL-1β-IL-1rII 
complexes and increases the receptors affinity for IL-1β (Boraschi and Tagliabue, 2013). IL-1β 
activity is also endogenously mediated by IL-1ra, which is an endogenous antagonist (Zheng et 
al., 1995). IL-1ra binds to IL-1r1 without initiating a biological response and subsequently 
inhibits the binding of IL-1β  (Zheng et al., 1995). 
The acute phase response has a long evolutionary history that has been highly conserved in both 
humans and animals, therefore the acute phase response in humans and animals is very similar 
(Bauhofer et al., 2001, Kluger, 1986), which enables the use of animal models of infection to 
explore aspects of the human sickness behaviour suite. During peripheral infections, pathogens 
colonize in the blood stream and activate peripheral immune cells (e.g. monocytes and 
macrophages) to release pro-inflammatory cytokines (Dantzer et al., 2000). Peripherally-released 
cytokines then signal the brain via both blood-borne and neural (the vagus nerve) routes which 
leads to secondary production of pro-inflammatory cytokines in the brain (Agyeman et al., 2014, 
Dantzer et al., 2000). Laboratory based studies frequently mimic peripheral bacterial infections 
by peripherally administering live bacteria (e.g. E. coli) (Barrientos et al., 2006), bacterial 
moieties (e.g. LPS) (Pugh et al., 1998) or pro-inflammatory cytokines (e.g. IL-1β, IL-6 or TNF-
α) (Begg et al., 1999). In fact, the majority of our understanding regarding host immune 
activation and the acute phase response is derived from rodent models of peripheral infection. 
Central infections can also occur independently of peripheral infections and are often either the 
result of focal infections which occur close to the brain (e.g. sinusitis or ottitis media) or in cases 
where the integrity of the skull or meninges is compromised (Agyeman et al., 2014). Central 
bacterial infections are induced in laboratory based studies by the direct administration of live 
bacteria (Barichello et al., 2013, Barichello et al., 2014b), bacterial moieties (McCarthy et al., 
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1986) or pro-inflammatory cytokines  (Harden et al., 2008) into the cerebral spinal fluid (CSF) 
of animals (Begg et al., 1999). 
Due to immunological immaturity in children and age related immunological declines in the 
elderly, these two demographic groups are at the highest risk for central infections and 
inflammation (Fietta et al., 1994, PrabhuDas et al., 2011), however central infections are still 
prevalent in healthy and immunocompromised adults (Begg et al., 1999). Laboratory based 
studies mimicking central bacterial infections have been well documented and have been studied 
at multiple developmental stages including neonatal (Bilbo and Schwarz, 2009), adolescence, 
adult hood (Harden et al., 2008) and old age (Barrientos et al., 2006). Interestingly, sickness 
responses are unique to each developmental stage and vary in terms of their intensity (Barrientos 
et al., 2009). As stated above, the acute phase response is very similar in humans and animals 
which makes rodents an ideal model for studying central infections because of ethical 
considerations. Therefore, in order to avoid confounding species-specific and age-specific 
sickness responses as well as any inaccurate immunological responses brought about due to 
using an immunocompromised animal I will concentrate on data from acute, central bacterial 
infections simulated in otherwise healthy, adult rats and mice for the remainder of my 
dissertation. 
Although laboratory based studies of fever and anorexia have been well documented following 
central bacterial infection and inflammation, little is known about lethargy and memory 
impairment in the context of central bacterial infections. In addition, to my knowledge, no 
studies have concurrently examined the impact of a central bacterial infection on a suite of 
physiological processes including body temperature, activity, food intake, body mass and 
memory. In this introductory chapter I will give a brief overview of the definitions and current 
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views in the literature regarding fever, anorexia, lethargy and memory impairment induced by 
simulated bacterial infection. Secondly, I will discuss the proposed mechanisms by which 
centrally administered LPS induces fever, anorexia, lethargy and memory impairment. Lastly I 
will discuss the proposed involvement of pro-inflammatory cytokines in mediating fever and 
sickness behaviours, with specific focus on the role of IL-1β.  
1.2. Fever  
 
During either pathogenic or simulated infection/inflammation, the host may develop a fever. 
Fever is a common accompaniment of the acute phase response and is characterized by an 
elevation in core body temperature (Conti et al., 2004, Romanovsky et al., 2005). Fever is the 
direct result of active thermogenic effectors and is achieved by an increase in heat production 
and/or by heat conservation mechanisms (Roth and Blatteis, 2014). Thermo-effector mechanisms 
are mediated by changes in neuronal activity localized in the preoptic nucleus of the anterior 
hypothalamus, which is the thermoregulatory centre of the brain (Conti et al., 2004).  
There are two thermosensitive neurons present in the pre-optic nucleus, namely warm-sensitive 
neurons (WSN) and cold-sensitive neurons (CSN). There are also neurons present in the 
hypothalamus that are not sensitive to changes in hypothalamic temperature, they are classified 
as temperature-insensitive neurons (ISN) (Boulant, 1998, Boulant, 2000). Whilst WSN appear to 
be intrinsically thermosensitive, evidence has suggested that CSN are not, instead they are 
dependent on synaptic input from neighbouring neurons (Boulant, 1998, Boulant, 2000, Hori et 
al., 1988, Kobayashi and Takahashi, 1993). During hypothalamic warming, WSN increase their 
firing rates. Which leads to synaptic inhibition of CSN and consequently decreases their firing 
rates (Boulant, 2000, Hori et al., 1988, Kobayashi and Takahashi, 1993). Inversely, during 
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hypothalamic cooling WSN decrease their activity, therefore synaptic inhibition to CSN will be 
reduced and resultantly CSN increase their firing rates (Boulant, 2000, Hori et al., 1988, 
Kobayashi and Takahashi, 1993). There is also evidence which suggests that CSN are open to 
excitatory synaptic input from the ISN (Boulant, 1998). The ISN maintain a constant excitatory 
synaptic input to the CSN so during hypothalamic cooling when WSN reduce synaptic inhibition 
to CSN the ISN (which are insensitive to hypothalamic temperature changes) maintain excitatory 
synaptic input to the CSN, which thereby increases CSN firing rates (Boulant, 1998). Once 
activated temperature-sensitive neurons innervate premotor neurons that drive autonomic 
thermo-effector responses in the body such as sweating and shivering (Boulant, 2000; Dinarello, 
2004). The everyday functioning of temperature-sensitive neurons under normal, non-
pathological circumstances leads to the establishment and homeostasis of core body temperature 
(Boulant, 1998). 
1.2.1. Fever in response to the central administration of LPS 
 
Under pathological conditions, multiple substances may initiate a fever (Roth and Blatteis, 
2014). Experimentally LPS is the most commonly used exogenous pyrogen used to study fever 
in the context of central infections. As shown in Table 1.1 the intracerebroventricular 
administration of LPS has been consistently demonstrated to induce a fever of rapid onset (~ 1 h) 
over a range of doses (10-60 ng) (Ledeboer et al., 2002, McCarthy et al., 1986). The direct 
administration of LPS into the cerebral ventricle of rats demonstrates the pyrogenic action of 
LPS, however it does not give any indication into the mechanism by which LPS induces fever. In 
fact, through radio-labelling studies it was discovered that pyrogens do not act directly via the 
pre-optic nucleus of the anterior hypothalamus to induce fever (Boulant, 1998, Boulant, 2000, 
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Hori et al., 1988). Rather, upon entry into the brain LPS activates immune cells (e.g. microglia, 
astrocytes, neurons and endothelial cells), which release endogenous pyrogens, specifically pro-
inflammatory cytokines (e.g. IL-1β, IL-6, TNF-α), which are the proximate mediators of fever 
(Roth and Blatteis, 2014). 
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Table 1.1: Summary of the studies that investigated the effect of LPS on core body temperature in rodents. 
 
IL-1β – Interleukin-1β, LPS – Lipopolysaccharide, IL-1ra – Interleukin -1 receptor antagonist, Anti-IL-1β – Interleukin-1β antibody, 
ICV – Intracerebroventricular, IP- Intraperitoneal, SC -Subcutaneous  
Attenuation suggests that body temperature was significantly decreased in comparison to rodents that received LPS, but was still 
significantly elevated compared to rodents that received the control substance.
 Species LPS dose and route Effect on core body temp Reference 
Lipopolysaccharide 
Central administration of: 
LPS Rats 10 ng, ICV Increase  McCarthy et al., 1986  
LPS Rats 60 ng, ICV Increase  Ledeboer et al., 2002 
 
 
Lipopolysaccharide and blocking IL-1 action 
Peripheral LPS and central administration of: 
IL-1ra Rats 100 μg/kg, IP Attenuation  Cartmell et al,. 1999 
IL-1ra Rats 100 μg/kg, IP Attenuation  Luheshi et al.,1996 
Caspase-1 inhibitor Rats 250  μg/kg, SC Attenuation Harden et al., 2011 
IL-1β knockout mice Mice 2.5 mg/kg, IP Attenuation  Kozak et al., 1998 
Anti-IL-1β Rats 50 mg/kg, IP Attenuation  Klir et al., 1994 
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Once pro-inflammatory cytokines have been released into the brain they bind to immune cells 
and cytokine specific receptors present in the pre-optic anterior hypothalamic area where they 
induce the expression of COX–2 and hence, prostaglandin-E2 (PGE2) (Conti et al., 2004, Roth 
and Blatteis, 2014). PGE2 then diffuses into the pre-optic nucleus and acts on PGE2 specific 
receptors present on thermosensitive neurons (Dinarello, 2004; Romanovsky et al., 2005). PGE2 
inhibits WSN activity which reduces synaptic inhibition to CSN (Boulant, 1998, Boulant, 2000) 
and this interaction results in thermogenesis and heat retention mechanisms such as cutaneous 
vasoconstriction, shivering and increased metabolic activity of brown adipose tissue; these 
integrated mechanisms cause febrigenesis (the onset of fever) (Boulant, 2000). When 
endogenous pyrogen levels decrease, WSN activity returns to normal which in turn decreases 
CSN activity and results in heat loss mechanisms (Boulant, 1998, Boulant, 2000). The heat loss 
mechanisms include: vasodilation, panting and sweating and enable defervescence (the 
resolution of fever) (Boulant, 2000).  
Studies in which LPS alone was administered centrally to rodents have demonstrated that LPS 
induces the synthesis of IL-1α, IL-1β, IL-6, and TNF-α, all of which are known to be 
intrinsically pyrogenic (Cunningham et al., 2005; Gabellec et al., 1995; Laye et al., 1994; Quan 
et al., 1998).  These cytokines have been described as intrinsically pyrogenic based on their 
innate ability to act individually and directly on the pre-optic nucleus of the hypothalamus, in 
both humans and rodents, to induce fever (Anforth et al., 1998, Busbridge et al., 1989, Conti et 
al., 2004, Dinarello, 1999, Harden et al., 2008).  To date the exact role of IL-1β in mediating 
fever during a central infection is still unclear. Table 1.1 shows the role of IL-1 in mediating 
fever induced by various doses (100 µg/kg – 50 mg/kg) of systemically administered LPS. There 
are no studies which have administered LPS centrally in conjunction with an IL-1 blocking 
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agent, therefore I included studies which administered LPS peripherally/systemically in 
conjunction with an IL-1 blocking agent. The proposed role of IL-1 in mediating fever was 
investigated using techniques which allowed for selective inhibition or blockade of IL-1. Studies 
in which brain IL-1 was blocked and which showed an attenuation of peripherally induced fever 
(Cartmell et al., 1999, Harden et al., 2011, Klir et al., 1994, Kozak et al., 1998, Luheshi et al., 
1996), indicate that IL-1 can act within the brain to mediate fever. In these studies, fever was 
measured by means of radiotelemetry (positioned in the abdomen of rodents) or by use of copper 
thermocouples (inserted into the rectum of rodents). 
Table 1.2 summarizes the pyrogenic effect of intracerebroventricularly administered IL-1β on 
core body temperature. Many studies adminstered IL-1β directly into the brain (Anforth et al., 
1998, Busbridge et al., 1989, Cao et al., 2001, Harden et al., 2008, Kent et al., 1992, Li et al., 
2001, Montkowski et al., 1997, Oitzl et al., 1993) and have demonstrated that IL-1β consistently 
initiates fever over a range of doses (0.1 ng – 20 µg). Fever was measured using radiotelemetry 
(positioned in the abdomen of rodents) or by use of copper thermocouples (inserted into the 
rectum of rodents). Collectively these studies suggest that IL-1β is a likely mediator of fever 
during a central infection.  
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Table 1.2: Summary of the studies that investigated the effect of intracerebroventricularly administered IL-1β on core body 
temperature in rodents. 
Species IL-1β dose and route Reference 
Rats 0.1 ng, ICV Montkowski et al., 1997 
Rats 1 ng, ICV Anforth et al.,1998 
Rats 1 ng, ICV Harden et al., 2008 
Rats 5 ng, ICV Anforth et al.,1998 
Rats 5 ng, ICV Busbridge et al., 1989 
Rats 5 ng, ICV Kent et al., 1992 
Rats 10 ng, ICV Anforth et al.,1998 
Rats 25 ng, ICV Cao et al., 2001 
Rats 100 ng, ICV Anforth et al.,1998 
Rats 100 ng, ICV Harden et al., 2008 
Mice 100 ng, ICV Li et al., 2001 
Rats 100 ng, ICV Montkowski et al., 1997 
Rats 100 ng, ICV Oitzl et al., 1993 
Rats 20 µg, ICV McCarthy et al., 1986 
 
ICV – Intracerebroventricular 
All studies reported an increase in body temperature following the intracerebroventricular administration of IL-1β 
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1.3. Anorexia  
 
Central infections in both humans and animals are frequently accompanied by anorexia (Hart, 1988, 
Plata-Salamán, 1996). Anorexia manifests as a decrease in food intake as well as an associated 
decrease in body mass (Sonti et al., 1996). The implementation of anorexia during illness is assumed to 
have both beneficial and deleterious consequences, dependent on its onset, duration and magnitude 
(Plata-Salamán, 1996). The potential for anorexia to have beneficial consequences seems paradoxical 
because implementation of the acute phase response constitutes a high energy demand. However, short-
term anorexia is hypothesized to decrease the availability of macro and micro-nutrients to invading 
pathogens, which causes a decrease in proliferation of invading bacteria or viruses (Hart, 1988; Plata-
Salamán, 1996). Long-term anorexia is associated with deleterious consequences. As energy 
expenditure exceeds energy input it can result in a net loss of body mass (Plata-Salamán, 1996). Long-
term loss of body mass can result in cachexia which is characterized by muscle and adipose tissue 
wasting, malnutrition, organism devitalisation and ultimately may lead to death (Plata-Salamán, 1996). 
The hypothalamus is hypothesized to be the primary site for regulation of feeding (Oomura, 1988, 
Plata-Salamán, 1996, Plata-Salamán et al., 1988). However, the mechanisms of anorexia are multi-
factorial; they involve hypothalamic modulation of feeding sites, modulation of endocrine release 
(insulin and glucagon) as well as gastro-intestinal modulation (gastric motility, emptying, acid 
secretion and intestinal motility) (Oomura, 1988, Plata-Salamán, 1996, Plata-Salamán et al., 1988). 
The hypothalamus has a dual center for the regulation of food intake (Plata-Salamán, 1998). These 
centers contain glucose-sensitive (GS) neurons and glucose-receptor (GR) neurons, which are present 
in the lateral hypothalamus and ventromedial hypothalamus respectively (Kuriyama et al., 1990, 
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Oomura, 1988, Plata-Salamán et al., 1988).  The GS and GR neurons are reciprocally linked and alter 
their activity in response to glucose and other metabolites (Kuriyama et al., 1990, Oomura, 1988, Plata-
Salamán et al., 1988).  In the presence of glucose, GS neurons decrease their activity and GR neurons 
increase their activity. The change in neuronal activity in response to the presence of glucose integrates 
chemical signals from other brain areas involved with satiation and causes a decrease in gut motility, an 
increase in peripheral secretion of insulin and glucagon and ultimately results in appetite suppression 
(Kuriyama et al., 1990, Oomura, 1988, Plata-Salamán, 1998, Plata-Salamán et al., 1988). The inverse 
is true when glucose levels are low (Kuriyama et al., 1990, Oomura, 1988, Plata-Salamán, 1998, Plata-
Salamán et al., 1988).  
1.3.1. Anorexia in response to the central administration of LPS 
 
A wide variety of pathogens have been shown to induce anorexia, but experimentally, LPS is one of the 
most commonly used pathogenic mimics used to study anorexia in the context of central bacterial 
infections. Intracerebroventricular administration of LPS, over a range of doses (3 ng – 2.5 µg), has 
consistently been shown to reduce both food intake and body mass (summarized in Table 1.3) (Bluthe 
et al., 1999, Bluthé et al., 2000, Burgess et al., 1998, Castanon et al., 2001, Faggioni et al., 1995), 
which confirms the anorexigenic ability of LPS.  However, LPS does not act directly on the 
hypothalamus to induce anorexia, rather upon entry into the brain LPS induces the release of pro-
inflammatory cytokines  which modulate anorexia (Plata-Salamán, 1996, Plata-Salamán, 1998).  
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Table 1.3: Summary of the studies that investigated the effect of LPS on food intake and/or body mass  of rodents. 
 
IL-1 – Interleukin-1, LPS – Lipopolysaccharide, IL-1ra – Interleukin -1 receptor antagonist, ICV – Intracerebroventricular  
Attenuation suggests that food intake and/or body mass were significantly increased in knockout mice compared to wild type mice 
that received LPS 
Ablation suggests that mice that were deficient in IL-1 converting enzyme were resistant to LPS and did not develop anorexia. 
 Species LPS dose and route Effect on food intake/ 
body mass 
Reference 
Lipopolysaccharide    
Central administration: 
LPS  Mice 3 ng, ICV Decrease Bluthé et al., 2000 
LPS Rats 60 ng, ICV Decrease Bluthé et al., 1999 
LPS Mice 100 ng , ICV Decrease Burgess et al., 1998 
LPS Rats 100 ng, ICV Decrease Castanon et al., 2001 
LPS Mice 2.5 µg, ICV Decrease Faggioni et al., 1995 
Lipopolysaccharide and blocking IL-1 action 
LPS IL-1 type 1 knockout mice 3 ng, ICV Attenuation Bluthé et al., 2000 
LPS IL-1 converting enzyme 
deficient mice 
100 ng, ICV Ablation  Burgess et al., 1998 
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Pro-inflammatory cytokines may modulate anorexia either by direct (via neuronal mechanisms) or 
indirect (via modulation of brain chemistry) action on the hypothalamus (Plata-Salamán, 1996, Plata-
Salamán, 1998). Pro-inflammatory cytokines that act directly on the hypothalamus increase the firing 
rate of GS neurons and decrease the firing rate of GR neurons, which will result in appetite suppression 
(Kuriyama et al., 1990; Oomura, 1988; Plata-Salamán et al., 1988). The hypothalamus also contains 
both neuropeptide and neurotransmitter systems which are related to feeding and appetite suppression. 
There is substantial data which shows that pro-inflammatory cytokines modulate hypothalamic 
chemistry by stimulating the synthesis and release of PGE2 and by interacting with neuropeptides and 
neurotransmitters within the brain. Research has demonstrated that PGE2 modulates anorexia by 
suppressing appetite (Dinarello, 2000, Levine and Morley, 1981). Pro-inflammatory cytokines have 
also been shown to up regulate the expression of corticotrophin releasing factor (CRF), which is an 
inhibitory neuropeptide that causes appetite suppression (Langhans and Hrupka, 1999, Plata-Salaman, 
1998), and downregulate the expression of neuropeptide-Y  (NP-Y), which is a potent promoter of 
feeding (Langhans and Hrupka, 1999, Plata-Salaman, 1998). Moreover, research has also demonstrated 
that the central administration of pro-inflammatory cytokines upregulates the secretion of 
catecholamines, serotonin and histamine, all of which contribute to the suppression of appetite 
(Langhans and Hrupka, 1999, Plata-Salaman, 1998). The collective modulation of brain chemistry via 
PGE2, CRF, NP-Y, catecholamines, serotonin and histamine causes appetite suppression and a resultant 
decrease in food intake. 
The pro-inflammatory cytokines that have been implicated in LPS-induced anorexia are IL-1β, IL-6 
and TNF-α (Plata-Salamán, 1996; Sonti et al., 1996; Harden et al., 2008). Studies in which researchers 
centrally administered individual or multiple combinations of IL-1β, IL-6 and TNF-α have determined 
that these pro-inflammatory cytokines can either act individually or synergistically in order to induce a 
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decrease in food intake which results in anorexia (Sonti et al., 1996; Harden et al., 2008). The 
synergistic action of pro-inflammatory cytokines is additive and induces anorexia of greater magnitude 
than the individual action of each of the cytokines, which supports the hypothesis that LPS-induced 
anorexia is mediated by a multi-cytokine interaction. Table 1.3 details the role of IL-1, specifically in 
mediating anorexia when induced by central LPS administration, which was investigated using 
techniques which allowed for selective inhibition or blockade of IL-1. Studies in which IL-1β was 
completely neutralised during central infections (summarized in Table 1.3) indicate that IL-1β can act 
within the brain to mediate anorexia because they resulted in the attenuation or complete ablation of 
LPS-induced anorexia (Bluthé et al., 2000, Burgess et al., 1998). Anorexia was determined by 
measuring change in food intake and change in body mass. 
Furthermore, studies in which IL-1β has been adminstered directly into the brain are summarized in 
Table 1.4 and have demonstrated that IL-1β is anorexigenic and consistently induces a decrease in both 
food intake and body mass over a range of doses (0.1-100 ng) (Bluthé et al., 1995, Bluthé et al., 2000, 
Harden et al., 2008, Kent et al., 1992, Kent et al., 1994, Montkowski et al., 1997, Sonti et al., 1996). In 
these studies anorexia in rats and mice was assessed by measuring food consumed, meal size, meal 
latency, food motivated behaviour and loss of body mass. Collectively these studies suggest that IL-1β 
is a likely mediator of anorexia during a central infection. 
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Table 1 4: Summary of the studies that investigated the effect of intracerebroventricularily administered IL-1β on food intake and/or 
body mass of rodents. 
 
 
ICV – Intracerebroventricular 
All studies reported a decrease in body mass and/or food intake following the intracerebroventricular administration of IL-1β 
Species IL-1β dose and route Reference 
Rats 0.1 ng, ICV Montkowski et al., 1997 
Rats 0.25 ng, ICV Sonti et al., 1996 
Rats 0.5 ng, ICV Plata-Salamán,  1994 
Rats 1 ng, ICV Plata-Salamán,  1994 
Rats 1 ng, ICV Sonti et al., 1996 
Mice 2 ng, ICV Bluthé et al., 2000 
Rats 2 ng, ICV Plata-Salamán,  1994 
Rats 4 ng, ICV Plata-Salamán,  1994 
Rats 5 ng, ICV Kent et al., 1994 
Rats 30 ng, ICV Bluthé et al., 1995 
Rats 30 ng, ICV Kent et al., 1994 
Rats 40 ng, ICV Kent et al., 1992 
Rats 90 ng, ICV Castanon et al., 2001 
Rats 100 ng, ICV Harden et al., 2008 
Rats 100 ng, ICV Montkowski et al., 1997 
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1.4. Lethargy  
 
Lethargy has been characterized as a change in the motivational state of an organism whereby it 
decreases its voluntary physical activity (Hart, 1988). Lethargy is a normal accompaniment of the 
acute phase response in both humans and animals and often accompanies fever (Harrington, 2012, 
Hart, 1988). It is hypothesized that lethargy plays a facilitative role in thermogenesis and a 
suppressive role in heat loss and energy expenditure (Hart, 1988). Lethargy results in a decrease in 
muscular activity accompanied by a decrease in energy demand which enables energy conservation 
for thermogenesis (Hart, 1988). Behavioural changes that accompany lethargy such as huddling and 
decreasing surface area also dramatically decrease heat loss (Hart, 1988). These changes in motility 
and position often negate the need for shivering and thus enable energy conservation (Hart, 1988).  
It has recently been established that lethargy comprises a small component of a much larger disorder  
known as fatigue (Harrington, 2012). Fatigue in rodents comprises of several symptoms namely a 
decrease in spontaneous, voluntary activity, altered sleep patterns and social interactions, increased 
anxiety like behaviour as well as impaired cognition, memory and attention (Harrington, 2012). 
The mechanisms of lethargy are largely unknown, however there are multiple neural networks that 
have been implicated in decreasing activity during infection or inflammation (Harrington, 2012). 
Associations have been made with the ventral tegmental area, the nucleus accumbens, the dorsal 
striatum and areas of the hippocampus (Harrington, 2012). Another school of thought has 
implicated arousal and motivational circuits in decreasing motivation for voluntary activity during 
pathological conditions by inhibiting input to the thalamus and cortex (Cheney, 1985, Harrington, 
2012).  
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1.4.1. Lethargy in response to the central administration of LPS 
 
Lethargy has been demonstrated after the administration of several experimental substances, 
including LPS, in several laboratories using rodent models of infection (Castanon et al., 2001, 
Harden et al., 2011, Kozak et al., 1997, Leon et al., 1996, Skinner et al., 2009). The effects of 
peripherally administered LPS on lethargy have been well described; however very little research 
has explored the effects of centrally administered LPS on lethargy. Nevertheless, similarly to 
peripherally administered LPS (Harden et al., 2011, Skinner et al., 2009) intracerebroventricularly 
administered LPS (100 ng) has been demonstrated to induce a decrease in observed motility in rats 
(Castanon et al., 2001) (see Table 1.5). Although the aforementioned studies show that LPS may 
induce lethargy, it is likely that LPS-induced pro-inflammatory cytokines are the proximate 
mediators of lethargy. 
Table 1.5 summarizes the research findings discussed in the section above that describe the effect of 
intracerebroventricularly administered LPS on cage activity, wheel running or observed mobility, all 
of which are measures of lethargy. The table also details the role of IL-1 in mediating lethargy 
induced by systemic LPS administration, which was investigated using techniques which allowed 
for selective inhibition or blockade of IL-1. There are no studies which have administered LPS 
centrally in conjunction with an IL-1 blocking agent, therefore I included studies which 
administered LPS peripherally/systemically in conjunction with an IL-1 blocking agent. Studies 
which block brain IL-1 and show attenuation of a peripheral LPS-induced decrease in voluntary 
activity (Harden et al., 2011, Kozak et al., 1995, Leon et al., 1996) give an indication that IL-1 can 
act within the brain to mediate lethargy. Although the exact role of IL-1β in mediating lethargy 
induced by central infections is unclear, studies in which IL-1β was antagonised or completely 
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neutralised during simulated peripheral infections using LPS (summarized in Table 1.5), show that 
IL-1β may or may not play a role in mediating lethargy because they caused either attenuation or 
had no effect on LPS-induced lethargy (Harden et al., 2011, Kozak et al., 1995, Leon et al., 1996).  
Therefore lethargy appears to be mediated by a multi-cytokine interaction. Lethargy was 
quantitatively measured as a decrease in activity which is characteristic of a state of lethargy in rats 
and mice. Changes in voluntary activity were either monitored via video camera or measured using 
radio telemetry. Voluntary wheel running was measured using running wheels.  
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Table 1.5: Summary of the studies that investigated the effect of LPS on voluntary activity in rodents 
 
IL-1β – Interleukin-1β, LPS – Lipopolysaccharide, ICV – Intracerebroventricular, IP- Intraperitoneal, SC- Subcutaneous , - indicates 
no effect 
Attenuation suggests that voluntary activity was significantly increased compared to rats that received LPS
 Species LPS dose and 
route 
Cage activity, observed 
mobility or wheel running 
Effect on 
activity 
Reference 
Lipopolysaccharide     
Central administration:     
LPS Rats 100 ng, ICV Observed mobility Decrease Castanon et al., 2001 
Lipopolysaccharide and blocking IL-1 action: 
Peripheral administration of: 
LPS IL-1 type1 
knockout mice  
50 μg/kg, IP Cage activity - Leon et al., 1996 
LPS IL-1β knockout 
mice 
2500 μg/kg, IP Cage activity - Kozak et al., 1995 
LPS IL-1 type 1 
knockout mice 
2500 μg/kg, IP Cage activity  - Leon et al., 1996 
Peripheral LPS and central administration of: 
Caspase-1 inhibitor Rats 250  μg/kg, SC Wheel running Attenuation Harden et al., 2011 
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As confirmation of the role that IL-1β plays as a mediator of lethargy during a central infection, 
studies in which IL-1β has been adminstered directly into the brain are summarized in Table 1.6 and 
have demonstrated that intracerebroventricularly adminstered IL-1β consistently induces a decrease 
in cage activity, wheel running and observed mobility in rats and mice, at a range of doses 0.1 ng – 
10 ng (Bluthé et al., 2000, Harden et al., 2008, Montkowski et al., 1997, Plata-Salamán, 1994). 
Voluntary activity was measured using running wheels, radiotelemetry or via subjective monitoring 
of observed activity. In addition a study in which IL-1β or IL-6 or a combination of the two pro-
inflammatory cytokines were administered intracerebroventricularly to rats showed that IL-1β and 
IL-6 can either act individually or synergistically to induce lethargy (Harden et al., 2008). However, 
the combined effect of IL-1β and IL-6 on lethargy was additive and resulted in lethargy of a greater 
magnitude than when compared to the individual effects of IL-1β and IL-6 (Harden et al., 2008), 
which lends credence to the hypothesis that lethargy is mediated by a multi-cytokine interaction.  
Collectively the data suggests that rodents in which IL-1β production is intact may rely partly on the 
expression of IL-1β for the development of lethargy. However, mice which are deficient in IL-1β or 
IL-1r1 may rely on different cytokine interactions in order to develop lethargy after the 
administration of LPS.   
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Table 1.6: Summary of the studies that investigated the effect of intracerebroventricularly IL-1β on voluntary activity in rodents  
Species IL-1β dose and route Cage activity, observed mobility or 
wheel running 
Reference 
Rats 0.1 ng, ICV Cage activity Montkowski et al., 1997 
Rats 0.1 ng, ICV Wheel running Harden et al., 2008 
Rats 0.25 ng, ICV Cage activity Plata-Salamán,  1994 
Rats 0.5 ng, ICV Cage activity Plata-Salamán,  1994 
Rats 1 ng, ICV Wheel running Harden et al., 2008 
Mice 2 ng, ICV Observed mobility Bluthé et al., 2000 
Rats 2 ng, ICV Cage activity Plata-Salamán,  1994 
Rats 4 ng, ICV Cage activity Plata-Salamán,  1994 
Rats 90 ng, ICV Observed mobility Castanon et al., 2001 
Rats 100 ng, ICV Wheel running Harden et al., 2008 
Rats 100 ng, ICV Cage activity Montkowski et al., 1997 
 
ICV – Intracerebroventricular   
All studies reported a decrease in voluntary activity following the intracerebroventricular administration of IL-1β
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1.5. Memory impairment  
 
In clinical cases of central bacterial infections (e.g. meningitis and brain abscesses), in addition to 
developing fever, lethargy and anorexia, one third of patients also present with cognitive deficits 
(Nau and Bruck, 2002).  The cognitive deficits in humans following central bacterial infections may 
include cognitive slowness, impairment of psychomotor and visuoconstructive performance and 
learning and memory deficits (Nau and Bruck, 2002, Nau et al., 1999, van de Beek et al., 2006, van 
de Beek et al., 2002). Learning and memory deficits are not only seen in clinical cases of central 
bacterial infections; experimental models have shown that rodents may also develop learning and 
memory impairment as a consequence of central bacterial infections (Barichello et al., 2014a, 
Barichello et al., 2013, Barichello et al., 2010, Barichello et al., 2014b).  
Memory does not exist as a single entity; there are several types of memory (see Figure 1.3) 
including short-term and long-term memory (Morris, 2001). Long-term memory is further sub-
divided into declarative and non-declarative memory (Phelps, 2004). Declarative memory refers to 
memories that are factual in nature and can be recalled (Phelps, 2004). There are several structures 
within the brain that are responsible for declarative memory namely the hippocampal formation, the 
basal ganglia and the prefrontal cortex; as such declarative memory is often referred to as 
hippocampal-dependent memory (Phelps, 2004). Non-declarative memory is described as  implicit 
in nature and refers to memories that are emotional and procedural (Phelps, 2004). The brain 
structure predominantly involved in non-declarative memory is the amygdala, hence non-declarative 
memory is often referred to as amygdala-dependent memory (Phelps, 2004). For the purposes of my 
study I will be focusing on hippocampal-dependent and amygdala-dependent memory, with specific 
focus on contextual and auditory-cued memory, for the remainder of my dissertation. 
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Figure 1.2: The types of memory adapted from (Morris, 2001). 
 
Learning, and ultimately the formation of a stable long-term memory involve the culmination and 
integration of a cascade of processes (see Figure 1.3). Memory acquisition is the initial process 
involved in the formation of a memory, it is the process of learning or acquiring new information 
(Abel and Lattal, 2001).  After acquisition the early memory is in a labile state (Abel and Lattal, 
2001) it then undergoes a period of consolidation which can take place anywhere between a few 
minutes to 24 hours (Abel and Lattal, 2001, Barrientos et al., 2002, Rudy et al., 2004). 
Consolidation allows the memory to be cemented into a fixed state and it is during this stage that 
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memories may either be interrupted or facilitated, thereafter the memory will either be stored as a 
complete or incomplete memory (Abel and Lattal, 2001, Barrientos et al., 2002). Memory retrieval 
is the last process in the cascade of memory processes and it is the point at which memories are 
recalled and the strength of their associations is tested (Abel and Lattal, 2001). 
 
Figure 1.3: Flow diagram showing the basic processes involved in memory formation. 
 
Memory impairment refers to an interruption in one or more of the processes involved in the 
formation of a memory. Multiple studies have explored the early processes involved in memory 
formation (i.e. acquisition and consolidation) in order to determine the stage at which it is most 
likely to be disrupted during infection or inflammation (Abel and Lattal, 2001, Thomson and 
Sutherland, 2006). The timing of pathogen administration relative to learning a task may indicate 
which memory process could be affected. Studies in which a pathogen is administered before 
learning a task will cause the animal being studied to be under the influence of the pathogen during 
and after learning and so acquisition or consolidation may be impaired (Cunningham and 
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Sanderson, 2008, Thomson and Sutherland, 2006). Whereas studies in which a pathogen is 
administered after learning a task will result in the animal being under the influence of the substance 
during memory consolidation and therefore memory consolidation may be impaired (Thomson and 
Sutherland, 2006).  
There are many experimental paradigms employed to specifically test long-term memory, one of the 
most well established and widely used in rodents is the contextual and auditory fear conditioning 
paradigm (Rudy et al., 2004), which measures both contextual and auditory-cued fear (Rudy et al., 
2004). During fear conditioning, immediately once a rat is placed into a novel environment, the rat 
will sample all the individual features of the environment and bind them together to form a 
contextual representation (Rudy et al., 2004). In the case of the fear conditioning task rats also 
experience a shock whilst they are in the novel environment and so the contextual representation for 
that environment will have a negative association (Rudy et al., 2004). Fear conditioning is 
theoretically based on Pavlovian (classical) conditioning (Maren, 2001) which takes into account an 
rodents instinctive survival behaviour to form environmental associations with aversive stimuli 
(Bouton and Moody, 2004, Phillips and LeDoux, 1992, Sanders et al., 2003). In the face of an 
aversive stimulus a rodent will exhibit its dominant fear response, namely freezing. Freezing is a 
common measure of conditioned fear in a rodent and is defined by the absence of all visible 
movement, excluding regular respiration (Barrientos et al., 2002).  Freezing often appears in 
conjunction with increased heart-rate, piloerection and defecation (Phillips and LeDoux, 1992, Rudy 
et al., 2004).  
1.5.1. Memory impairment in response to the peripheral administration of LPS 
 
Using several different memory paradigms and routes of administration, several laboratories have 
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examined the effects of LPS on the formation of memory in order to examine its effect on either 
memory acquisition or memory consolidation. To my knowledge no animal studies have examined 
the effect of centrally administered LPS on memory acquisition or memory consolidation using fear 
conditioning therefore I will discuss studies which examined the effects of peripherally administered 
LPS on hippocampal-dependent memory in rodents. Interestingly, to my knowledge no studies have 
examined the effect of peripherally administered LPS specifically on memory acquisition using fear 
conditioning. However, to date three studies measured hippocampal-dependent memory acquisition 
following the peripheral administration of LPS using other paradigms (e.g. the cued lever-press task 
(Aubert et al., 1995), the passive avoidance paradigm (Sparkman et al., 2005) and the Morris water 
maze (Sparkman et al., 2006)). Although in all studies LPS was administered peripherally and 
immediately before acquisition the effect of on memory acquisition was different; in two of the 
studies LPS caused inhibition of memory acquisition (Aubert et al., 1995, Sparkman et al., 2005), 
whereas another study reported that LPS had no impact on memory acquisition (Sparkman et al., 
2006). Together these studies conclude that the relationship between peripherally administered LPS 
and memory acquisition is complex. Unlike the relationship between centrally administered LPS 
and other sickness responses, LPS does not seem to consistently induce hippocampal-dependent 
memory impairment. 
The complex relationship between LPS administration and memory impairment was echoed in 
studies that examined the effect of peripherally administered LPS specifically on memory 
consolidation: in these studies LPS was administered immediately or 30 min after fear conditioning 
(Pugh et al., 1998, Terrando et al., 2010) (see Table 1.7). As seen in Table 1.7, the peripheral 
administration of LPS to rats selectively induced hippocampal-dependent memory impairment 
(Pugh et al., 1998, Terrando et al., 2010). Interestingly at the low dose of 0.5mg/kg and the high 
32 
 
dose of 2 mg/kg, peripherally administered LPS had no effect on memory, whereas the midrange 
dose of 1 mg/kg caused hippocampal-dependent memory impairment (Pugh et al., 1998, Terrando et 
al., 2010). Collectively these studies suggest that LPS may act on hippocampal-dependent memory 
in a U-shaped dose response. One possible explanation for this phenomenon was suggested by Pugh 
et al. (1998); high doses of LPS may cause the prolonged release of corticosterone, which has 
previously been demonstrated to enhance performance in the fear conditioning paradigm (Pugh et 
al., 1997). Furthermore, LPS is known to induce the expression of pro-inflammatory cytokines, 
including IL-1β (Conti et al., 2004), a high dose of LPS may have induced a significant 
overexpression of IL-1β, which has in some instances been shown to enhance hippocampal-
dependent memory performance (Goshen et al., 2007). 
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Table 1.7: Summary of the studies that investigated the effect of peripherally administered LPS on learning and memory 
in rodents 
 Species LPS dose and 
route 
Time of injection Memory 
paradigm 
Effect on 
memory 
Reference 
Lipopolysaccharide      
Peripheral administration of: 
LPS Rats 0.5 mg/kg, IP Immediately after 
conditioning 
Fear 
conditioning 
No effect Pugh et al., 1998 
LPS Rats 1 mg/kg, IP Immediately after 
conditioning 
Fear 
conditioning 
HD memory 
impairment  
Pugh et al., 1998 
LPS Mice 1 mg/kg, IP 30 min after  
conditioning 
Fear 
conditioning 
HD memory 
impairment 
Terrando et al,. 2010 
LPS Rats 2 mg/kg, IP Immediately after 
conditioning 
Fear 
conditioning 
No effect Pugh et al., 1998 
Peripherally administered Lipopolysaccharide and blocking IL-1 action 
Peripheral administration of: 
 
IL-1ra Rats 0.5 mg/kg, IP Immediately after 
conditioning 
Fear 
conditioning 
Attenuation - 
HD memory  
Pugh et al., 1998 
IL-1ra Mice 1 mg/kg, IP 30 min after 
conditioning 
Fear 
conditioning 
Attenuation - 
HD memory  
Terrando et al,. 2010 
 
HD memory – Hippocampal-dependent memory, IL-1β – Interleukin-1β, LPS – Lipopolysaccharide, IL-1ra – Interleukin -1 receptor 
antagonist,  IP- Intraperitoneal 
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The central action of several pro-inflammatory cytokines induced by LPS, specifically IL-1β, IL-6 
and TNF-α, have been shown to play a neuromodulatory role in memory (Goshen and Yirmiya, 
2006). Although no studies have administered an IL-1 blocking agent in conjunction with central 
LPS injection, Table 1.7 summarizes the effect on memory following peripherally administered LPS 
in conjunction with a peripherally administered selective IL-1 antagonist. These studies, which 
attempted to block IL-1, showed attenuation of peripheral LPS-induced memory impairment (see 
Table 1.7) and may indicate that IL-1 is a likely mediator of memory impairment during infection. 
The contextual and auditory fear conditioning paradigm was used in order to assess memory in 
these studies (Pugh et al., 1998, Terrando et al., 2010).  
The role of IL-1β in mediating hippocampal-dependent memory in rodents has been extensively 
studied in many laboratories, using several different memory paradigms. There are no studies to my 
knowledge which have examined the effect of centrally administered IL-1β on memory acquisition 
using fear conditioning. However, several studies have examined the effect of centrally 
administered IL-1β on memory acquisition using other memory paradigms (e.g. the lever-press 
avoidance task (Brennan et al., 2004), eye-blink response test (Servatius and Beck, 2003), the 
Morris water maze (Gibertini, 1998) and the inhibitory avoidance paradigm (Depino et al., 2004)) 
which also test hippocampal-dependent memory. Although in all studies IL-1β was administered 
centrally, immediately before acquisition the effect of IL-1β on memory acquisition was different; 
in three of the studies IL-1β caused facilitation of acquisition (Brennan et al., 2004, Gibertini, 1998, 
Servatius and Beck, 2003) however, one study showed that centrally administered IL-1β caused 
inhibition of memory acquisition (Depino et al., 2004). Together these studies suggest that, similar 
to LPS, IL-1β also has a complex relationship with memory and does not consistently induce 
memory impairment. 
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The complex relationship between IL-1β and memory was also seen in studies that examined the 
effect of centrally administered IL-1β specifically on memory consolidation (see Table 1.8). In all 
these studies IL-1β was administered immediately after and up to 24 h after fear conditioning. The 
majority of studies listed in Table 1.8 have demonstrated that the acute intracerebroventricular or 
intrahippocampal administration of IL-1β over a range of doses (2 ng - 20 ng), caused hippocampal-
dependent memory impairment  (Barrientos et al., 2002, Barrientos et al., 2004, Goshen et al., 2007, 
Hein et al., 2007, Pugh et al., 1999). However, despite the findings that elevated levels of IL-1β in 
the brain may be detrimental to memory consolidation, the intracerebroventricular administration of 
a low dose (1 ng) of IL-1β caused an improvement in hippocampal-dependent memory (Goshen et 
al., 2007), suggesting IL-1β may also be beneficial to memory. Moreover, studies which blocked 
basal levels of IL-1β (see Table 1.8), using pharmacological and genetic means, caused 
hippocampal-dependent memory impairment (Avital et al., 2003, Goshen et al., 2007), suggesting 
that low and/or basal levels of IL-1β may be necessary for memory consolidation. Collectively, all 
the data discussed above suggests that IL-1β exerts its influence on memory consolidation in an 
inverted U-shaped pattern (Goshen and Yirmiya, 2006). The inverted U-shaped hypothesis suggests 
that low or basal levels of IL-1β in the brain are necessary for memory consolidation and may even 
play a beneficial role in improving memory (Goshen and Yirmiya, 2006). However, deviation from 
the basal level of IL-1β either by excessively elevated levels or by antagonizing IL-1β may have a 
detrimental effect on memory and subsequently cause memory impairment (Goshen and Yirmiya, 
2006). 
36 
 
Table 1.8: Summary of the studies that investigated the effect of centrally administered IL-1β on learning and memory in rodents. 
 Species IL-1β dose and 
route 
Time of injection Memory 
paradigm 
Effect on 
memory 
Reference 
Interleukin - 1β      
Central administration: 
 Mice 1 ng, ICV Immediately after 
conditioning 
Fear 
conditioning 
HD memory 
improvement 
Goshen et al., 2007 
 Rats 2 ng, IH Immediately, 3 h, and 
24 h after conditioning 
Fear 
conditioning 
HD memory 
impairment 
Barrientos et al., 
2002 
 Rats 10 ng, IH Immediately after 
conditioning 
Fear 
conditioning 
HD memory 
impairment 
Barrientos et al., 
2004 
 Mice 10 ng, ICV Immediately after 
conditioning 
Fear 
conditioning 
HD memory 
impairment 
Goshen et al., 2007 
 Rats 10 ng, IH Immediately after 
conditioning 
Fear 
conditioning 
HD memory 
impairment 
Hein et al., 2007 
 Rats 10 ng, ICV Immediately after 
conditioning 
Fear 
conditioning 
HD memory 
impairment 
Pugh et al., 1999 
 Rats 20 ng, ICV Immediately after 
conditioning 
Fear 
conditioning 
HD memory 
impairment 
Pugh et al., 1999 
Blocking  basal levels of IL-1β      
IL-1ra Mice - Immediately after 
conditioning 
Fear 
conditioning 
HD memory 
impairment 
Goshen et al., 2007 
IL-1 type 1 knockout mice Mice - - Fear 
conditioning 
HD memory 
impairment 
Avital et al., 2003 
 IL-1ra over-expression Mice - - Fear 
conditioning 
HD memory 
impairment 
Goshen et al., 2007 
 
HD memory – Hippocampal-dependent memory,  IL-1β – Interleukin-1β,  IL-1ra – Interleukin -1 receptor antagonist, ICV – 
Intracerebroventricular, IH - Intrahippocampal
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1.6. Dissertation hypotheses and aims 
 
I hypothesize that immune activation in the brain will concurrently induce fever, anorexia, 
lethargy and memory impairment. 
The findings presented in the sections above have highlighted that the acute, central administration 
of LPS seems to consistently induce fever, anorexia and lethargy in rodents. Although peripheral 
administration of LPS has been shown to induce memory impairment in rodents, no study to date 
has examined the effect of centrally administered LPS on memory in rodents. Additionally no study 
has examined the effects of central LPS-induced fever, lethargy and food intake, whilst concurrently 
examining memory.  
Therefore I undertook an experiment which aimed at concurrently examining the dose-dependent 
effect of LPS administered via the cisterna-magna on body temperature, activity, food intake, body 
mass and memory of rats. Memory was assessed using the fear conditioning task, which measures 
both hippocampal-dependent and amygdala-dependent memory. Importantly, conditioning/learning 
took place immediately before rats received an intra-cisterna magna injection of either LPS or 
vehicle. Following the intra-cisterna magna injection of LPS rats became febrile, lethargic and 
anorexic however, surprisingly rats did not show memory impairment.  
Having failed to reject the null hypothesis and identifying a dissociation between fever, lethargy, 
anorexia and memory processes when rats were conditioned before receiving LPS, I undertook a 
second experiment aimed at investigating the dynamics of this dissociation and developed a new 
hypothesis.  
I hypothesize that immune activation in the brain will differentially affect abdominal 
temperature, voluntary activity, food intake and body mass as compared to cognitive function. 
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During the second experiment I injected rats centrally with IL-1β, as central IL-1β has been 
demonstrated to be a predominant mediator in the initiation of fever, anorexia, lethargy and also 
memory impairment. Body temperature, activity, food intake, body mass and memory were 
measured following a single ICM injection of IL-1β. Importantly, conditioning/learning took place 
either immediately before or 2 h after the rats received an intra-cisterna magna injection of IL-1β. 
The purpose of conditioning the rats at different time points, i.e. either before or after receiving IL-
1β, was to examine the time course by which memory interference could occur, relative to increased 
IL-1β concentrations in the brain, in conjunction with the presentation of the other sickness 
responses. In addition, I also measured the time course of IL-1β synthesis in the hippocampus and 
hypothalamus after the ICM injection of IL-1β. 
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Chapter 2 
Materials and Methods 
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2.1. Experimental animals and housing 
 
Adolescent male Sprague-Dawley rats (initial body mass 80-100g) were obtained from the National 
Health Laboratory Service (NHLS, Johannesburg, South Africa) and housed individually in cages in 
the Central Animal Service at the University of the Witwatersrand.  The rats were housed at an 
ambient temperature of 22 ± 1 C on a 12:12 light-dark cycle. Rats were initially housed on a light-
dark cycle from 07:00-19:00. However, for behavioural experiments the light-dark cycle was 
changed to 03:00-15:00 to accommodate injections occurring during working hours. For brain 
sample collection a different group of rats were housed on a light-dark cycle from 12:00-24:00, for 
ease of termination at the 8 h time point which took place at 17:00. The changes in light-dark cycles 
of the rats occurred 3 weeks before surgery (described below) in order for the rats to acclimatize to 
the new cycle. Food (pelleted rat chow, Epol, Johannesburg, South Africa) and water were provided 
to the rats ad libitum. All experimental procedures were performed in accordance with the 
regulations described in the University of the Witwatersrand guide for the care and use of laboratory 
animals and approved by the Animal Ethics Screening Committee of the University of the 
Witwatersrand (AESC2012/08/04; AESC2012/38/04; AESC2013/28/04). 
2.2. Surgery 
 
All rats weighed approximately between 150-200g, and were considered adults at the time of 
surgery, for intraperitoneal implantation of precalibrated temperature and activity sensitive 
radiotransmitters (TA101A-F40, Data Sciences, St. Paul, MN, USA). Rats were anaesthetized with 
an intramuscular injection of a combination of ketamine hydrochloride (100 mg/kg) (Anaket-V, 
Bayer, SA) and xylazine (5mg/kg) (Chanazine, Bayer, SA). Once anaesthetized, the surgical area 
was shaved and cleaned with veterinary disinfectant (Health and Hygiene, Sunninghill, South 
Africa). A 50 mm incision was made through the skin and muscle, into the peritoneal cavity. The 
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radiotransmitter (30x15x10 mm; ~8g) was inserted into the abdomen and left as “free floating” in 
the peritoneal cavity, thereafter the wound was sutured. After surgery the animals received a single 
injection of atipamezole hydrochloride (100 mg/kg) (Pfizer, Sandton, South Africa) to promote 
recovery from anaesthesia. After surgery the rats were housed in a warm recovery room (~27C) for 
5 hours and then they were returned to their cages for an additional seven day period of recovery. 
 
2.3. Body temperature and activity 
 
Abdominal temperature and cage activity were measured continuously using implanted 
radiotransmitters (TA101A-F40, Data Sciences, St. Paul, MN, USA). The output from the implanted 
radiotransmitters (frequency in Hz) was monitored using a receiver plate (33x23x3 cm) (RPC-1, 
Data Sciences, St. Paul, MN, USA), placed under each rat’s cage. The data from the 
radiotransmitters were logged every 5 min into a processor (DP-24, Data Port, Vital View, 
MiniMitter, Sunriver, OR, USA) and the signal relayed to a computer. The radiotransmitters were 
calibrated to an accuracy of 0.01 °C in a water bath at 35 C and 39 C by the manufacturer. The 
temperature was encoded in the radiotransmitter pulse repetition rate, which was recorded at each 
temperature using the 2-calibration-point method. The calibration values were calculated for each 
transmitter by the manufacturer. 
2.4. Food intake and body mass 
 
Food intake and body mass of rats were measured daily at the same time every day approximately 4 
hours before the beginning of the dark cycle using an electronic scale (Avery weigh-tronix, UK) 
accurate to 1g. Rats were weighed and their food containers filled during their day time a few hours 
before the beginning of their dark cycle as they are largely inactive and do not consume much food 
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during this time. Food containers were filled daily with 200 g of standardized, pelleted rat chow and 
food intake of rats was determined by subtracting the food left in the food container and on the cage 
floor from the initial amount of food given (200 g) at the preceding time each day. 
2.5. Memory 
 
2.5.1. Contextual and auditory fear conditioning 
 
Fear conditioning was used as an experimental tool for measuring memory in rats. The contextual 
and auditory fear conditioning paradigm is a well established model used to test for learning and 
memory and has been used in many laboratories (Barrientos et al., 2002, Goshen et al., 2007, Hein 
et al., 2007, Pugh et al., 1999). 
2.5.1.1. Apparatus and behavioural procedure 
 
The contextual and auditory fear conditioning apparatus used in my study consisted of two large, 
isolation chambers (106 x 76 x 80 cm), each housing another smaller chamber (30 x 25 x 30cm) 
(see Figure 2.1). One chamber (A) is referred to as the “context chamber” and was equipped with a 
stainless steel grid floor as well as a speaker, which was located at the back of the chamber. Another 
chamber, referred to as the “auditory chamber” (B), also was equipped with a speaker but differed 
significantly from the context chamber: it consisted of a smooth, perspex floor and a cage divider (5 
cm in height) that divided the cage diagonally. The walls of the auditory chamber were covered by a 
zebra print pattern and the cage floor was lined with tissue paper. A red block and two egg cartons 
were placed onto the chamber floor. The purpose of having two different chambers was to test for 
the two different types of memory.  
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I followed a typical fear conditioning protocol, which consisted of three phases: a conditioning 
phase and two testing phases. During conditioning a rat was placed into the context chamber (A) for 
2 min after which a 15 s tone was presented over the speaker, followed by a single, 2 s foot shock. 
The tone was produced by a frequency generator set at 1 kHz and amplified to 70 db. The amplitude 
of the tone was measured at the entrance to the chamber using a sound level meter (TES-1357, TES 
Electrical Electronic corp, Tapei, Taiwan). The foot shock (1.5 mA) was produced by a current 
generator (Coulbourn Instruments, Allentown, PA) and delivered via the grid floor. 
During the conditioning phase rats were individually transported in black buckets with lids into our 
fear conditioning laboratory and placed into the context chamber (A) where they were presented 
with a tone and received a foot shock. Rats were then immediately removed and transported back to 
their home cages (again in black buckets with lids). We used black buckets with lids to transport the 
rats to and from the fear conditioning laboratory to ensure that the rats could not see out of the 
Figure 2.1: Illustration of the experimental setup for contextual and auditory fear 
conditioning and testing in our laboratory. The context chamber (A) is used for testing 
contextual fear conditioning, while the auditory chamber (B) is used to test for auditory 
fear conditioning. 
 
A B 
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bucket; the bucket with the lid became a contextual cue which indicated to the rats that they were 
being transported to and from the context chamber. The context chamber (A) was cleaned with 
disinfectant (F10 Veterinary disinfectant, Health and Hygiene, Sunninghill, South Africa) before the 
next rat was conditioned. 
Seven days after conditioning two memory tests were performed on each rat. The first test, namely 
the contextual fear test, assessed hippocampal-dependent memory of rats after their initial exposure 
to the context chamber (A). Similarly to the conditioning phase, the rats were individually 
transported (in black buckets with lids) to the fear conditioning laboratory and placed into the 
context chamber (A). Once rats were placed into the context chamber they were allowed to explore 
freely for 6 min, during the entire duration of this test rats did not experience either a tone or a 
shock. During the 6 min period rats were scored, every 10 s, as either active or freezing by two 
observers blind to the experimental intervention. After the 6 min testing-period rats were 
immediately removed from the context chamber and transported back to their home cages (again in 
black buckets with lids). After testing each rat, the context chamber was cleaned with disinfectant 
(F10 Veterinary disinfectant, Health and Hygiene, Sunninghill, South Africa). 
The second test, namely the auditory fear test, assessed amygdala-dependent memory of rats and 
took place 3 hours after the contextual fear test. During this test rats were transported two at a time, 
using a white bucket with no lid, from their home cages to the fear conditioning laboratory and 
placed into one of two, separate auditory chambers (B). Once rats were placed into their respective 
auditory chambers they were allowed to explore freely for 3 min; this part of the test is referred to 
throughout my dissertation as the pre-tone period. Exploration was followed by presentation of a 
tone for 3 min; this part of the test is referred to throughout my dissertation as the post-tone period. 
For the entire 6 min period, rats were scored every 10 s for freezing behaviour. At cessation of the 
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test, rats were removed immediately and transported back to their home cages (two at a time in a 
white bucket with no lid). Rats were transported in twos in a white bucket with no lid in order to 
provide the rats with a different experience whilst being carried to the auditory chamber, this was 
important to ensure that the rats did not associate the new method of transportation with the negative 
experience of the foot shock they had in the context chamber. After testing each rat the auditory 
chamber was cleaned with water, as opposed to disinfectant, to ensure that the cage did not smell 
the same as the context chamber, in this case smell could also act as a reminder of the negative 
experiences in the context chamber.  
I created the protocol for fear conditioning and testing using Graphic state Notation 4 software 
(Coulbourn Instruments, Allentown, PA). Presentation of both the tone and foot shock were 
controlled by a Habitest self-powered linc (Coulbourn Instruments, Allentown, PA).  
Table 2.1: Summary of the procedures followed in each of the three phases of fear 
conditioning  
 
 
 
 
 
  
 Conditioning Contextual fear test  Auditory fear test 
Transport of 
rats: 
 
Individual 
Black bucket with lid 
Individual 
Black bucket with lid 
Two rats 
White bucket, no lid 
Timing: 
 
Exploration – 2 min 
Tone – 15 s 
Shock 2 s 
Exploration - 6 min Exploration ( pre-tone) – 3 
min 
Exploration with tone – 3 
min 
Scoring: 
 
Every 10 s for 2 min Every 10 s for 6 min Every 10 s for 6 min 
Cleaning: 
 
Context chamber and 
bucket cleaned with 
disinfectant 
Context chamber and 
bucket cleaned with 
disinfectant 
Auditory chamber and 
bucket cleaned with water 
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2.5.1.2. Validation of fear conditioning 
 
Fear conditioning is not a novel behavioural method for assessing memory experimentally, however 
it was novel in our hands. In order to validate fear conditioning and testing in our laboratory, I made 
use of a pharmacological challenge using scopolamine hydrobromide (Sigma-Aldrich, St Louis, 
MO, USA), a known amnesic drug. Scopolamine is an anti-cholinergic drug (Gravius et al., 2006, 
Sanders et al., 2003) that is frequently used in studies as a positive control, to induce short-term 
memory impairment in laboratory animals (Gravius et al., 2006, Rudy, 1996, Sanders et al., 2003). 
Both hippocampal-dependent and amygdala-dependent memory seem to be mediated by cholinergic 
input from the medial septal nucleus and nucleus basalis magnocellularis, respectively (Rudy, 
1996). Scopolamine is thought to affect both of these central pathways by interrupting post trial 
processing that leads to memory formation (Rudy, 1996).  
The dose 0.8 mg/kg of scopolamine hydrobromide (Sigma-Aldrich, St Louis, MO, USA) was 
chosen for my validation study based on a study whereby rats were injected peripherally with 0.8 
mg/kg of scopolamine hydrobromide and showed significant memory impairment (Rudy, 1996). 
The timing of scopolamine administration (before or after conditioning) was also chosen based on a 
study wherein the researcher stated that peripherally administered scopolamine induced sufficient 
amnesia, whether it is injected (10 or 30 min) before or after conditioning (Rudy, 1996). I chose to 
inject scopolamine 30 min before conditioning as well as 30 min before the contextual and auditory 
fear tests based on a study which demonstrated that serum levels of peripherally administered 
scopolamine hydrobromide peak approximately 30 min after injection (Ebert et al., 1998). 
Moreover, whether scopolamine is administered peripherally or centrally does not seem to influence 
its effect on memory (Wallenstein and Vago, 2001), therefore I chose to administer scopolamine 
peripherally.  
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Figure 2.2 shows that the peripheral administration of scopolamine hydrobromide induced 
significant memory impairment in rats.   Figure 2.2 A shows that during the contextual fear test, rats 
which received scopolamine froze significantly less than rats that received saline (t (11) =12.18, P < 
0.001), which gives an indication that rats that received scopolamine had hippocampal-dependent 
memory impairment. Figure 2.2 B shows the freezing behaviour of rats during the auditory fear test. 
During the pre-tone period rats that received scopolamine and saline froze to a similar extent 
(t(6)=1.81, P > 0.05). However, during the post-tone period rats that received scopolamine froze 
significantly less than rats that received saline (t(7) =12.31, P < 0.001), which indicates that rats 
which received scopolamine had amygdala-dependent memory impairment.  
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Figure 2.2: Freezing behaviour during the contextual fear test (A) and the auditory fear 
test (B) for rats that received a single IP injection of 0.8 mg/kg of scopolamine 
hydrobromide (n = 10) or 1 ml/kg saline (n = 10). During each test each rat was either 
judged as freezing or mobile every 10 s at the instant the measurement was taken. The 
number of positive freezing scores were summed for each observer and an average 
freezing score between the observers was obtained. The average freezing score wa s 
divided by the number of sampling bocks for each test and multiplied by 100 to express 
the freezing behaviour as a percentage. Significant differences: * Saline vs Scopolamine. 
The results are represented as means ± SD. 
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2.6. Intra-cisterna magna injections 
 
Administration of substances to rodents via the cisterna magna have been commonly used in other 
laboratories (Barrientos et al., 2012, Frank et al., 2010, Proescholdt et al., 2000). However, it was 
the first time that this procedure was setup and performed in our laboratory. For my study I injected 
lipopolysaccharide (LPS), interleukin - 1β (IL-1β) and their vehicles, phosphate buffered saline 
(PBS) and 0.1% bovine serum albumin (BSA) respectively, into the cisterna magna of rats. 
Before all intra-cisterna magna (ICM) injections rats were placed into a gas chamber and 
anaesthetized using isoflurane, an inhalable anesthetic (see Figure 2.3A). Once anesthetized the 
dorsal aspect of the rats’ skull was shaved and cleaned with 70 % ethanol (see Figure 2.3B). A 26-
gauge needle (Kendon Medical Supplies, Johannesburg, South Africa) which was connected to a 50 
μl Hamilton gastight microlitre syringe (Hamilton, Switzerland) by polyethylene tubing (0.38 mm 
inner diameter, 1.09 mm outer diameter) (see Figure 2.3C), was inserted into the cistern magna (see 
Figure 2.3 D and E). To confirm the correct positioning of the needle in the cistern magna, 3 μl of 
CSF was drawn up: if the CSF was clear of blood it verified the correct entry into the cistern magna. 
Rats that had blood in the CSF were excluded from all data analysis, as entry of the drug into the 
cistern magna could not be verified (n = 12). After verification of entry into the cistern magna 5 μl 
of the appropriate experimental substance (LPS or IL-1β) or vehicle (PBS or BSA) was 
administered and the needle was left in the cisterna magna, for 30 s, to ensure total dispersal of the 
substance.  After recovery from anesthesia each rat was returned to its home cage. 
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A B 
C D 
E 
Figure 2.3: Preparation for intra-cisterna magna injections. (A) Anaesthesia given in a gas-
chamber using inhalable isoflurane. (B) Preparation of the rat’s skull for ICM injection. (C) 
Example of a 50 μl Hamilton syringe used during ICM injection. (D) Locating the cisterna 
magna at the posterior part of the skull at the midline of the ears. (E) Insertion of the needle into 
the cisterna magna at a 90angle. 
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2.6.1 Pyrogens and control substances 
 
LPS derived from E. coli endotoxin (serotype 011:B4, Sigma, St Louis, MO, US) was reconstituted 
in sterile PBS and injected via the cisterna magna at either 10 or 100 µg. The doses of LPS were 
chosen based on studies which peripherally administered LPS to adult rats at 10 and 100 µg 
(Cartmell et al., 1999, Luheshi et al., 1996) and in neonatal studies in which rat pups were injected 
intracerebroventricularly with 10 µg of LPS (Pang et al., 2003). Both peripheral and 
intracerebroventricular injections of LPS have been shown to induce the synthesis and release of 
pro-inflammatory cytokines in the brain including IL-1β (Conti et al., 2004, Pang et al., 2003). Rat 
recombinant IL-1β (501-RL, R&D Systems, Minneapolis, MN, USA) was reconstituted in sterile 
0.1% BSA and injected via the cisterna magna at a dose of 100 ng. The 100 ng dose of IL-1β was 
chosen based on previous studies in which IL-1β (100 ng) was administered 
intracerebroventricularly to rats and induced fever, lethargy and anorexia (Anforth et al., 1998, 
Harden et al., 2008). 
2.7. Brain tissue collection 
 
In order to measure IL-1β in the brains of rats injected via the cisterna magna with IL-1β, I perfused 
the rats and collected hypothalamus and hippocampus samples. Rats were perfused at 1 h, 2 h, 4 h, 8 
h and 24 h after intra-cisterna magna injection. These time points were chosen based on temperature 
profiles obtained in my study following the intra-cisterna magna administration of IL-1β to rats. The 
basic fever profile following the intra-cisterna magna administration of IL-1β (100 ng) to rats 
included: the rising phase typically starting ~ 1 h after intra-cisterna magna injection, the plateau 
phase occurring between 4 - 6 h and defervescence at ~ 8 h. 
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For perfusions rats were anaesthetized with a single intaperitoneal injection of 0.8 ml sodium 
pentobarbital (Euthapent, 200 mg/ml; Kyron Laboratories (Pty) Ltd., South Africa). The chest 
cavity of the rat was exposed, a catheter was inserted through the left ventricle into the aorta and the 
rat was transcardially perfused using cold, sterile saline (0.9 %) for approximately 3 min. The rat 
was then decapitated and the brain was removed from the skull. The hypothalamus and both 
hippocampi were quickly dissected on an ice-cold plate and placed into individual, sterile, plastic 
tubes, which were snap frozen in liquid nitrogen. All tissue samples were stored at – 80 C until 
used in the enzyme-linked immunosorbent assays (ELISA) described below. 
2.8 Interleukin-1β analysis 
 
Hippocampi and hypothalamus samples were removed from the – 80 C freezer to thaw and kept on 
ice at approximately 4 C. The use of the left or right hippocampus was randomized between rats 
for IL-1β analysis. Thereafter 300 μl of sonication buffer (50 mM Tris base, 100 mM Amino-n-
caproic acid, 1 mM Ethylenediaminetetraacetic acid, 5 mM Benzamidine and 0.2 mM 
Phenylmethylsulfonylflouride) was pipetted into each tube containing the tissue. Each tube was 
placed individually into a beaker full of ice and the tissue was sonicated for approximately 10 s 
using an ultrasonic cell disruptor (Microson XL 2000, Newton, CT, USA) to dissociate the tissue. 
Sonicated tissue samples were then centrifuged at 4 C at 14000 rpm for 10 min. After 
centrifugation approximately 250 μl of the supernatant was placed into a 1.5 ml sterile, plastic tube, 
which was kept on ice (~ 4 C) until used in the ELISA. Bradford protein assays (Bradford, 1976) 
were performed to determine total protein concentrations in each sonicated sample. The Bradford 
standards were prepared using a serial dilution of 0.1% BSA and distilled water. Concentrations 
used were 1000 µg/ml, 800 μg/ml, 600 μg/ml, 400 μg/ml, 200 μg/ml, 100 μg/ml and 50 μg/ml. 
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Protein samples were prepared using a 1:20 dilution. Once the samples had been diluted 5 µl of each 
diluted sample was pipetted into individual wells on a 96 well-plate. Thereafter 250 μl of Bradford 
reagent (Sigma-Aldrich, Saint-Louis, Missouri, USA) was pipetted into each well and the plate was 
incubated for 15 min at room temperature. After incubation protein absorbance was measured at 595 
nm. 
Concentrations of IL-1β were determined using a commercially-available Quantikine ELISA kit 
(R&D Systems, Minneapolis, MN) for rat IL-1β. The microplate used in the ELISA was pre-coated 
with an affinity purified polyclonal antibody specific for IL-1β. Fifty microlitres of the provided 
assay diluent was added to each well followed by 50 μl of sample, standard or control (samples 
were tested in duplicate). The plate was then covered and incubated at room temperature for 2 
hours. After washing away any unbound substances, rat conjugate IL-1β (100 μl) was added to each 
well and incubated at room temperature. After another wash to remove any unbound conjugate, 
substrate solution (100 μl) was added to each well and the plate was protected from light and 
incubated for 30 min. Thereafter a stop solution (100 μl) was added to each well in order to 
terminate the enzyme reaction. Sample optical density was determined using a microplate reader set 
at 450 nm and 540 nm and IL-1β concentrations were calculated by  interpolation from a standard 
curve obtained from rat recombinant IL-1β (31.2-100 µg/ml). Data were corrected for protein 
concentration and the results expressed as pictograms of IL-1β per milligram of protein. 
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2.9 Experimental procedures 
 
2.9.1 Experiment 1 – Lipopolysaccharide 
 
All rats were implanted intraperitoneally with radiotransmitters and allowed to recover for 7 days 
(see Figure 2.4). Thereafter, rats were randomly assigned to either an experimental group which 
received LPS (10 µg (n = 10) or 100 µg (n = 3)) or a control group which received PBS (n = 9). 
Following recovery from surgery rats were conditioned in the fear conditioning task (~12:00) (as 
described in section 2.5). Immediately (~ 5 min) after conditioning, rats received a single intra-
cisterna magna injection (5 μl) of either LPS (10 µg or 100 µg) or PBS. Abdominal temperature, 
activity, food intake and body mass were measured for 7 days after injection. By day 7 the sickness 
behaviours experienced by the rats that received LPS had resolved and then memory of rats was 
tested in both the contextual and auditory fear tests. Contextual fear of rats was tested at 7:00, 8 h 
before the onset of the daily dark phase (15:00). Auditory fear of rats was tested 3 h after testing for 
contextual fear. Rats were excluded from data analysis if blood was present in the CSF during intra-
cisterna magna injection (n = 4) or if rats presented with a significant hypothermia below 32 °C (n = 
2). 
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Figure 2.4: Basic flow diagram showing the order and timing of surgery and behavioural 
experiments for rats which were conditioned before receiving an ICM injection.  
 
2.9.2. Experiment 2 – Interleukin-1β 
 
2.9.2.1. Part A - Behavioural experiments 
 
All rats were implanted intraperitoneally with radiotransmitters and allowed to recover for 7 days. 
Thereafter, rats were randomly assigned to either an experimental group in which they received IL-
1β (100 ng) or a control group in which they received 0.1% BSA. Following recovery from surgery, 
rats were either conditioned immediately before (IL-1β: n = 13, BSA: n = 5) (see Figure 2.4) or 2 h 
after (IL-1β: n = 10, BSA: n = 9) (see Figure 2.5) receiving a single intra-cisterna magna injection 
(5 μl) of IL-1β (100 ng) or 0.1% BSA. The two hour delay in conditioning was chosen based on 
temperature profiles which showed that by 2 h after intra-cisterna magna injection rats were in the 
rising phase of fever. Abdominal body temperature, activity, food intake and body mass were 
measured for 7 days. By day 7 the sickness behaviours experienced by the rats that received IL-1β 
had resolved and then memory of rats was tested in both the contextual and auditory fear tests. 
Contextual fear of rats was tested at 7:00, 8 h before the onset of the daily dark phase (15:00). 
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Auditory fear of rats was tested 3 h after testing for contextual fear. . Rats were excluded from data 
analysis based on three criteria, blood present in the CSF (n = 6), abnormal temperature data, such 
as the lack of fever (n = 2) or being an outlier as calculated using the Grubbs test (n = 1) for any of 
the memory tests. 
 
Figure 2.5: Basic flow diagram showing the order and timing of surgery and behavioural 
experiments for rats which were conditioned after receiving an ICM injection 
 
2.9.2.2. Part B - Sample collection 
 
All rats were implanted intraperitoneally with radiotransmitters and were allowed to recover for 7 
days. Thereafter, rats were randomly assigned to either an experimental group which received 100 
ng of IL-1β or a control group which received 0.1% BSA.  Following recovery from surgery rats 
were either conditioned immediately before (IL-1β: n = 28, BSA: n = 16) or 2 h after (IL-1β: n = 34, 
BSA: n = 27) receiving a single intra-cisterna magna injection (5 μl) of IL-1β (100 ng) or 0.1% 
BSA. Rats were then terminated and brain tissue samples (hypothalamus and hippocampi) were 
collected at 1 h, 2 h, 4 h, 8 h and 24 h after intra-cisterna magna injection (see Figure 2.6).  
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Figure 2.6: Basic flow diagrams showing the order and timing of sample collections for 
rats which were conditioned before (A) or after (B) receiving an ICM injection. 
 
 
 
 
 
 
A 
B 
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2.10. Data analyses 
 
Temperature responses for rats were plotted as abdominal temperature-time curves in 1 or 2 hour 
intervals. For statistical analysis the original 5-min temperature recordings for each rat were 
averaged over 2 hours. The 2-hourly means were then analyzed by means of a two-way repeated 
measures ANOVA (with intervention and time as main effects), with a Bonferroni post hoc test 
when the ANOVA showed significance. 
Change in nocturnal cage activity (15:00-3:00) of rats was calculated as the difference between the 
sum of night-time activity following injection and the average sum of night-time activity in the three 
day period before injection and expressed as a percentage of the pre-injection activity. Food intake 
was measured daily and calculated as grams of food consumed in 24 hours per 100 g of body mass 
and expressed as a percentage change from the mean daily food intake measured over three days 
before injection. Twenty-four hour change in body mass was determined by subtracting the body 
mass measured on each day after the injection from the body mass measured immediately before the 
injection and expressed as the change in body mass (g) per 100 g of rat body mass. Changes in 
nocturnal activity, food intake and body mass were compared by means of a two-way repeated 
measures ANOVA (with intervention and time as main effects), with a Bonferroni post hoc test 
when the ANOVA showed significance. 
To assess memory, freezing behaviour during conditioning, the contextual fear test and the auditory 
fear test was assessed individually for each rat by 3 observers, blind to the experimental 
intervention. Inter-rater reliability, i.e. the consensus between scorers, exceeded 95% for all 
experiments. During conditioning and both memory tests, each rat was judged every 10 s as either 
mobile or freezing at the instant the sample was taken. Scoring began 10 s after the rat was placed 
into the relative context and continued every 10 s for 2 min during conditioning and 6 min during 
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the contextual fear and auditory fear (3 min pre-tone and 3 min post-tone) tests. The number of 
positive freezing scores were summed for each observer and an average freezing score between the 
observers was obtained. The average freezing score was divided by the number of samples taken for 
each test and multiplied by 100 to express the freezing behaviour as a percentage. Scores were then 
compared using a one-way ANOVA with a Bonferroni post-hoc test when the ANOVA showed 
significance. 
Brain IL-1β concentrations were compared over 5 time points (1 h, 2 h, 4 h, 8 h and 24 h) using a 
two-way ANOVA (with intervention and time as main effects) with a Bonferroni post hoc test to 
determine inter and intra-group interactions when the ANOVA showed significance. Concentrations 
of IL-1β were compared separately for the hypothalamus and the hippocampus.  
Data were expressed in terms of means and standard deviations and statistical significance was set 
at P < 0.05. 
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3.1. Experiment 1 - Lipopolysaccharide 
 
3.1.1. Abdominal temperature 
 
Figure 3.1 shows the abdominal temperature responses over 72 h for rats that received intra-cisterna 
magna injections of PBS or LPS (either 10 µg or 100 µg) (main effect of time (F(36,684) = 41.7, P < 
0.001), intervention (F(2,19) =3, P > 0.05) and interaction (F(72,684) = 30.5 , P < 0.001)). After 
injection, the abdominal temperatures of rats that received both doses of LPS started to decrease 
significantly within 1-2 h after injection (P < 0.05, Bonferroni). Approximately 2 h after injection, 
in comparison to rats that received PBS, the abdominal temperatures of the rats that received 10 µg 
and 100 µg of LPS differed by ~ 1 °C and ~ 1.5 °C respectively. By the end of night 1 the LPS-
induced hypothermia had resolved for both doses of LPS (10 and 100 µg). By day 1 after injection 
rats that received 10 µg of LPS had a significantly greater abdominal temperature than rats that 
received PBS. The fever noted in the rats that received 10 µg of LPS peaked at 38.1 ± 0.4 °C, ~ 10 h 
after injection (P < 0.05, Bonferroni). By day 2 the fever induced by 10 µg of LPS had resolved and 
rats that received 100 µg of LPS began to show a significantly greater abdominal temperature than 
rats that received PBS and 10µg of LPS (P < 0.05, Bonferroni). The fever induced by 100 µg of 
LPS peaked at 38.2 ± 0.2 °C, ~ 36 h after injection and resolved by the end of day 3 (P < 0.05, 
Bonferroni). The dose-dependent effect of LPS (10 µg and 100 µg) was evident throughout the three 
days after injection. The hypothermia induced by 100 µg of LPS reached lower temperatures and 
lasted longer (~ 14 h) than the hypothermia induced by 10 µg of LPS (~ 6 h) (P < 0.05, Bonferroni). 
Both doses of LPS induced a fever of similar magnitude and duration, however rats that received 10 
µg of LPS reached the peak of the fever sooner (~10 h) than rats that received 100 µg of LPS (~36 
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h). The abdominal temperatures of rats, 48 h prior to injection, were not significantly different from 
each other. 
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Figure 3.1 - The abdominal temperatures of rats 72 h after receiving a single ICM injection 
of 5 μl of PBS (n = 9), 10 µg of LPS (n = 10) or 100 µg of LPS (n = 3). The abdominal 
temperatures of rats were plotted in 2 h intervals. Statistical analysis was conducted on the 
original 5-min temperature recordings for each rat which were averaged over 2 hours. The 
arrow indicates the time of injection and the black bars indicate lights off. Significant 
differences: * PBS vs 10 µg LPS; # PBS vs 100 µg LPS; $ 10 µg LPS vs 100 µg LPS. 
Results are represented as mean  ± SD. 
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3.1.2. Nocturnal cage activity 
 
Figure 3.2 shows that the central administration of LPS caused a decrease in nocturnal cage activity 
for 4 nights after injection compared to rats that received PBS (main effect of time (F(5,95) = 54.9, P 
< 0.001), intervention (F(2,19) = 29, P < 0.001) and interaction (F(10,95) = 6.4, P < 0.001)). On the 
first night after injection, irrespective of dosage, LPS induced a maximum decrease in nocturnal 
cage activity of ~ 80% (P < 0.001, Bonferroni). The decrease in nocturnal cage activity was dose-
dependent only on night two after injection and rats that received 100 µg of LPS showed a larger 
decrease in nocturnal activity than rats that received 10 µg of LPS (P < 0.01, Bonferroni). 
Thereafter rats gradually became more active and by night 5 nocturnal activity was not significantly 
different between groups.   
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Figure 3.2 - Nocturnal cage activity of rats after receiving a single ICM injection of 5 μl of PBS (n = 
9), 10 µg of LPS (n = 10) or 100 µg of LPS (n = 3). Change in nocturnal cage activity was 
calculated as the difference between the sum of night-time activity following injection and the 
average sum of night-time activity in the three day period before injection and expressed as a 
percentage of the pre-injection activity, with – 100% indicating a complete cessation of nocturnal 
cage activity. Significant differences: * PBS vs 10 µg LPS; # PBS vs 100 µg LPS; $ 10 µg LPS vs 
100 µg LPS. Results are represented as mean ± SD. 
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3.1.3. Food intake and body mass 
 
On average, rats consumed between 9 and 11 g of food, per 100g of body mass, per day during the 3 
days before experimental intervention. Figure 3.3 shows that LPS induced a decrease in food intake 
(A) and body mass (B). Rats that received LPS (10 and 100 µg) consumed less food for 2 days after 
injection when compared to rats that received PBS (main effect for time (F(5,95)= 191.3, P < 0.001), 
intervention (F(2,19)= 18.2, P < 0.001) and interaction (F(10,95)= 49.5, P < 0.001). The magnitude of 
the decrease in food intake was dose-dependent and rats that received 100 µg of LPS consumed 
significantly less food on day 1 and 2 as compared to rats that received 10 µg of LPS (P < 0.05, 
Bonferroni). Following the initial decrease in food intake rats that received LPS gradually began to 
eat more food and on days 3 and 4 after injection food intake was similar between groups (P > 0.05, 
Bonferroni). As shown in Figure 3.3B, rats that received LPS also showed a significant, dose-
dependent, loss of body mass for 4 days after injection when compared to rats that received PBS 
(main effect for time (F (3,57) = 36.8, P < 0.001), intervention (F (2,19) = 156, P < 0.001) and 
interaction (F (6,57) = 3, P < 0.05)). Rats that received 100 µg of LPS lost more body mass over the 4 
days after injection as compared to rats that received 10 µg of LPS (P< 0.05, Bonferroni). 
Thereafter, rats gradually started to regain body mass and body mass was not significantly different 
between groups. 
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Figure 3.3 - Food intake (A) and body mass (B) of rats that received a single ICM injection of 5 μl 
of PBS (n = 9), 10 µg of LPS (n = 10) or 100 µg of LPS (n = 3). Food intake was calculated as the 
grams of food consumed in 24 hours per 100 g of body mass and expressed as a percentage change 
from the mean daily food intake measured over three days before injection. Twenty-four hour 
change in body mass was determined by subtracting the body mass measured on each day after the 
injection from the body mass measured immediately before the injection and expressed as the 
change in body mass (g) per 100 g of rat body mass. Significant differences: * PBS vs 10 µg LPS; # 
PBS vs 100 µg LPS; $ 10 µg LPS vs 100 µg LPS. Results are represented as mean ± SD. 
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3.1.4. Memory 
 
Figure 3.4 shows the freezing behaviour of rats during conditioning (A), the contextual fear test (B) 
and the auditory fear test (C). Figure 3.4A shows that during conditioning, which took place 
immediately before any intervention, all rats were between 95 - 100% active in the context chamber, 
although rats which received 100 µg of LPS froze significantly more (~ 5 %) than rats that received 
PBS and 10 µg LPS (F(2,18)= 12.7, P < 0.05). Figure 3.4B shows that during the contextual fear test 
rats that received LPS (10 and 100 µg) and PBS showed similar freezing behaviour (between ~ 55 -
85 %) (F(2,18) = 3.2, P > 0.05). Figure 3.4C shows that during the pre-tone period of the auditory 
fear test rats which received LPS (10 and 100 µg) froze to a similar extent (~ 40 – 60 %). Moreover, 
rats which received 10 µg of LPS froze to a similar extent to rats that received PBS (~ 25 - 40%). 
However, rats which received 100 µg of LPS froze significantly more (~35 %) than rats that 
received PBS (F(2,19)= 5, P < 0.05). There were no differences in freezing behaviour between rats 
that received LPS (10 and 100 µg) and PBS during the presentation of the tone (F(2,19)=  0.04, P  > 
0.05). 
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Figure 3.4 - Freezing behaviour during conditioning (A), the contextual fear test (B) and the 
auditory fear test (C) for rats that received a single ICM injection of PBS (n = 9), 10 µg of LPS (n = 
10) or 100 µg of LPS (n = 3). During each test each rat was either judged as freezing or mobile 
every 10 s at the instant the measurement was taken. The number of positive freezing scores were 
summed for each observer and an average freezing score between the observers was obtained. The 
average freezing score was divided by the number of sampling bocks for each test and multiplied by 
100 to express the freezing behaviour as a percentage.Significant differences: # PBS vs 100 µg LPS; 
$ 10 µg LPS vs 100 µg LPS. Results are represented as mean ± SD. 
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3.2. Experiment 2 - Interleukin-1β 
 
3.2.1. Part A – Behavioural experiments 
 
3.2.1.1. Abdominal temperature 
 
Figure 3.5 shows that rats which received a single ICM injection of IL-1β had a significant rise in 
abdominal temperature after a latent period of ~ 2 h compared to rats which received BSA (main 
effects of time (F(24,840)  = 127.4, P < 0.001), intervention (F(1,35) = 135.7, P < 0.001) and interaction 
(F(24,840)  = 34.5, P < 0.001)). The abdominal temperature of rats injected with IL-1β peaked at 38.9 
± 0.3 °C, ~ 6 h after injection and remained significantly elevated compared to rats that received 
BSA during day 1 and day 2 after injection (P < 0.05). By the end of day 2 the IL-1β-induced fever 
appeared to resolve and the abdominal temperatures of rats that received IL-1β were not 
significantly different to rats that received BSA (P > 0.05).  The abdominal temperatures of rats, 48 
h prior to injection, were not significantly different from each other. The abdominal temperatures 
for rats that were conditioned immediately before or 2 h after they received BSA were not 
significantly different from each other and subsequently, the data for the groups were combined. 
Similarly, the abdominal temperatures for rats that were conditioned before or 2 h after they 
received IL-1β were not significantly different from each other and therefore the data for the groups 
were combined. 
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Figure 3.5 - The abdominal temperatures of rats 48 h after receiving a single ICM injection of 5 μl 
of 100 ng of IL-1β (n = 23) or 0.1% BSA (n = 14). Abdominal temperature was plotted in 1 hour 
intervals. Statistical analysis was conducted on the original 5-min temperature recordings for each 
rat which were averaged over 2 hours. The arrow indicates the time of injection and the black bars 
indicate lights off. Significant differences: 
* 
BSA vs 100 ng IL-1β. Results are represented as mean 
± SD. 
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3.2.1.2. Nocturnal cage activity 
 
Figure 3.6 shows that rats that received a single ICM injection of IL-1β had a decrease in nocturnal 
cage activity for two nights after injection compared to rats that received BSA (main effect of time 
(F(3,105) = 43.7, P < 0.001), intervention (F(1,35) = 22.1, P < 0.001) and interaction (F(3,105) = 6.6, P < 
0.05)). During night 1 after injection, IL-1β induced a maximum decrease in nocturnal activity of 62 
± 17 % (P < 0.001, Bonferroni). Thereafter rats gradually became more active and by night 3 after 
injection nocturnal cage activity was not significantly different between rats that received BSA and 
IL-1β. The nocturnal cage activities for rats that were conditioned immediately before or 2 h after 
they received BSA were not significantly different from each other and subsequently, the data for 
the groups were combined. Similarly, the nocturnal cage activities for rats that were conditioned 
before or 2 h after they received IL-1β were not significantly different from each other and therefore 
the data for the groups were combined. 
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Figure 3.6 - Percentage change in nocturnal cage activity of rats after receiving a single ICM 
injection of 5 μl of 100 ng of IL-1β (n = 23) or 0.1% BSA (n = 14). Change in nocturnal cage 
activity was calculated as the difference between the sum of night-time activity following injection 
and the average sum of night-time activity in the three day period before injection and expressed as 
a percentage of the pre-injection activity, with – 100% indicating a complete cessation of nocturnal 
cage activity. Results are represented as mean ± SD. 
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3.2.1.3. Food intake and body mass 
 
On average, rats consumed between 8 and 12 g of food, per 100 g of body mass, per day for 3 days 
before experimental intervention. Figure 3.7 shows that rats which received IL-1β had a decrease in 
both food intake (A) and body mass (B). Figure 3.7A shows that the central injection of IL-1β 
caused rats to consume less food than rats that received BSA (main effect of time (F(3,105)= 131.1, P 
< 0.001), intervention (F(1,35)= 16.3, P < 0.05) as well as interaction (F(3,105)= 21.2, P < 0.001)) for 2 
days after injection (P < 0.001, Bonferroni). Figure 3.7B shows that rats which received IL-1β also 
lost body mass compared to rats that received BSA (main effect of time (F (3,105) = 28.3, P < 0.001), 
intervention (F (1,35) = 32.8, P < 0.001)  and interaction (F (3,105) = 13.2, P < 0.001)). The body mass 
of rats which received IL-1β remained decreased for 3 days compared to rats that received BSA (P 
< 0.001, Bonferroni).  Following the first day after injection rats that received IL-1β began to regain 
body mass and by day 4 their body mass was similar to the body mass of rats that received BSA. 
The food intake and body mass of rats that were conditioned immediately before or 2 h after they 
received BSA were not significantly different from each other and subsequently, the data for the 
groups were combined. Similarly, the food intake and body mass of rats that were conditioned 
before or 2 h after they received IL-1β were not significantly different from each other and therefore 
the data for the groups were combined. 
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Figure 3.7 – The food intake (A) and body mass (B) of rats that received a single ICM injection of 5 
μl of 100 ng of IL-1β (n = 23) or 0.1% BSA (n = 14). Food intake was calculated as the grams of 
food consumed in 24 hours per 100 g of body mass and expressed as a percentage change from the 
mean daily food intake measured over three days before injection. Twenty-four hour change in body 
mass was determined by subtracting the body mass measured on each day after the injection from 
the body mass measured immediately before the injection and expressed as the change in body mass 
(g) per 100 g of rat body mass. Significant differences: 
* 
BSA vs 100 ng IL-1β. Results are 
represented as mean ± SD. 
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3.2.1.4. Memory 
 
Figure 3.8 shows that the freezing behaviour seen during conditioning (A), the contextual fear test 
(B) and the auditory fear test (C) was dependent on the time point at which rats were conditioned 
relative to receiving an ICM injection of IL-1β. Figure 3.8A shows that rats which received BSA 
and rats that were conditioned before they received IL-1β explored the context with equal interest 
during conditioning and were active most of the time (F(2,27)= 7.4, P < 0.05). However, rats that 
were conditioned 2 hours after receiving IL-1β explored the context with less freedom and froze for 
approximately 13 % of the time during conditioning, which was significantly more than rats that 
were conditioned before they received IL-1β and rats that received BSA (P < 0.001, Bonferroni). 
Figure 3.8B shows the freezing behaviour of rats during the contextual fear test. Rats that were 
conditioned 2 hours after receiving IL-1β froze approximately 45% less than rats that received BSA 
and rats that were conditioned before receiving IL-1β (F(2,34)= 17.4, P < 0.001). However, rats that 
received BSA and rats that were conditioned before receiving IL-1β showed similar freezing 
behaviour (~ 65 %) to each other (P < 0.001, Bonferroni). Figure 3.8C shows that during the 
auditory fear test rats which were conditioned 2 h after receiving IL-1β froze significantly less 
during both the pre-tone (P < 0.001, Bonferroni) and post tone (P < 0.001, Bonferroni)  periods 
than rats that received BSA and rats that were conditioned before receiving IL-1β. Again rats that 
received BSA and rats that were conditioned before receiving IL-1β froze similarly to each other 
during both the pre-tone (~ 30 %) (F(2,34)= 15.1, P < 0.001) and post tone periods (~ 85 %) (F(2,34)= 
17.5, P < 0.001).  Rats that were conditioned immediately before or 2 h after they received BSA 
froze similarly during conditioning, the contextual fear test and the auditory fear test, subsequently 
the data for the groups were combined for each test. 
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Figure 3.8 – Freezing behaviour during conditioning (A), the contextual fear test (B) and the 
auditory fear test (C) for rats that were: (1) conditioned immediately before receiving a single ICM 
injection of 100 ng of IL-1β (n = 13); (2) conditioned 2 h after receiving a single ICM injection of 
100 ng of IL-1β (n = 10) or that received 0.1% BSA (n = 14). During each test each rat was either 
judged as freezing or mobile every 10 s at the instant the measurement was taken. The number of 
positive freezing scores were summed for each observer and an average freezing score between the 
observers was obtained. The average freezing score was divided by the number of sampling bocks 
for each test and multiplied by 100 to express the freezing behaviour as a percentage. Significant 
difference: 
*
Rats conditioned after receiving 100 ng of IL-1β compared to rats receiving BSA and 
rats conditioned before receiving 100 ng IL-1β. Results are represented as mean ± SD. 
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3.2.2. Part B – Sample collections 
 
3.2.2.2. Concentration of IL-1β in the brain 
 
Figure 3.9 shows that a single ICM injection of 100 ng of IL-1β induced a significant increase in IL-
1β concentrations in two brain areas at several different time points after injection. Figure 3.9A 
shows that rats which received IL-1β had significantly increased IL-1β concentrations in the 
hypothalamus compared to rats that received BSA (main effect of time (F(4,83) = 17.6, P < 0.001), 
intervention (F(1,83) = 34.2, P < 0.001) and interaction (F(4,83) = 2.7 , P < 0.05)) at 1 h, 4 h and 8 h 
after injection (P < 0.05, Bonferroni). However, there were no significant differences in 
hypothalamic IL-1β concentrations of rats that received IL-1β between 1 – 8 h after injection (P < 
0.05, Bonferroni). There also were no significant differences in hypothalamic IL-1β concentrations 
of rats that received BSA from 1 – 24 h after injection (P > 0.05, Bonferroni). Figure 3.9B shows 
that rats which received IL-1β had significantly increased IL-1β concentrations in the hippocampus 
compared to rats that received BSA (main effect of time (F(4,83) = 6.8, P < 0.001), intervention 
(F(1,83) = 43.9, P < 0.001) and interaction (F(4,83) = 2.8, P < 0.05)) at 1 h, 4 h and 8 h after injection 
(P < 0.05, Bonferroni). There were no significant differences in hippocampal IL-1β concentrations 
of rats that received IL-1β between 1 – 8 h after injection (P < 0.05, Bonferroni). There were no 
significant differences in hippocampal IL-1β concentrations of rats that received BSA from 1 – 24 h 
after injection (P > 0.05, Bonferroni). The hypothalamic and hippocampal IL-1β concentrations of 
rats that were conditioned immediately before or 2 h after they received BSA were not significantly 
different from each other and subsequently, the data for the groups were combined. Similarly, the 
hypothalamic and hippocampal IL-1β concentrations of rats that were conditioned before or 2 h 
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after they received IL-1β were not significantly different from each other and therefore the data for 
the groups were combined. 
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Figure 3.9 - Hypothalamic (A) and hippocampal (B) IL-1β concentrations in rats at several time 
points following a single ICM injection of 5 µl of 100 ng of IL-1β (n = ~ 11 per time point) or 0.1% 
BSA (n = ~ 7 per time point). The black line indicates the period during which there was no 
significant difference in IL-1β concentrations in the brain for rats receiving IL-1β after injection. 
Significant differences: 
*
BSA vs 100 ng IL-1β. Results are represented as mean ± SD. 
79 
 
 
 
 
 
 
 
 
 
 
Chapter 4  
Discussion 
  
80 
 
The results of the present study have shown that the intra-cisterna magna administration of LPS to 
rats dose-dependently induces profound sickness responses including: a biphasic temperature 
response, lethargy and anorexia. Interestingly, even though the rats injected with LPS developed 
profound sickness responses, their hippocampal-dependent memory remained intact. Although the 
findings that centrally administered LPS induces fever, anorexia and lethargy is not novel, to my 
knowledge this is the first study that concurrently examined the effect of LPS administered via the 
cisterna magna to rats on a suite of sickness responses. Furthermore, my study is the first to have 
examined the effect of centrally administered LPS on memory consolidation in rats using fear 
conditioning.  
Moreover, I have also shown that the intra-cisterna magna administration of IL-1β to rats induces 
fever, lethargy and anorexia, as well as an increase in hypothalamic and hippocampal IL-1β 
concentrations for up to 8 h following injection. Additionally, I demonstrated that the time point at 
which IL-1β is administered to rats, in relation to when they were conditioned (i.e. when learning 
takes place), plays a significant role in whether a rat will develop memory impairment or not. I 
found that IL-1β administered 2 h before conditioning induced both hippocampal and amygdala-
dependent memory impairment, whereas IL-1β administered immediately after conditioning had no 
effect on memory. While the characterization of sickness responses after the central administration 
of IL-1β is not novel, what is novel in my study was the concurrent examination of the effect of IL-
1β administered via the cisterna magna on body temperature, activity, food intake, body mass and 
memory. Furthermore, my study was the first to characterize the expression of IL-1β in the brain 
following an intra-cisterna magna injection of IL-1β. 
Despite all the studies undertaken to date which used the third cerebral ventricle as the route of 
central injection for pathogenic substances to rodents, I chose to inject both LPS and IL-1β via the 
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cisterna magna of rats. Research on cannulae implantation, which is required for 
intracerebroventricular injection, showed that the implantation of cannulae causes activation of 
inflammatory transcription factors within the brains of rodents (Damm et al., 2013) and requires a 
3-4 week recovery period (Pugh et al., 1999). Intra-cisterna magna injections do not require 
cannulae implantation but rather the direct injection of substances into the cisterna magna of 
rodents, therefore rodents only require a short recovery from anesthesia. Moreover, to my 
knowledge no studies have determined that intra-cisterna magna injection causes either immune or 
microglial activation.   
4.1. LPS-induced sickness responses 
 
My findings support the view that centrally administered LPS is a potent exogenous pyrogen and 
can act within the brain to induce fever. Previous research has consistently shown that the 
intracerebroventicular administration of LPS at a range of doses (10 – 60 ng) induces a monophasic 
fever (Ledeboer et al., 2002, McCarthy et al., 1986), however the temperature profiles attained in 
my study after the intra-cisterna magna administration of LPS (10 and 100 µg) showed a dose-
dependent hypothermia followed by the development of a fever (see Figure 3.1). Although 
hypothermia may be uncommon after the central administration of LPS, the temperature profile in 
my study is very similar to the mild hypothermias which precede fevers often seen after 
intermediate doses (0.5 – 5 mg/kg) of peripherally or intravenously administered LPS (Leon, 2004, 
Liu et al., 2012, Romanovsky et al., 1996, Romanovsky et al., 1997, Romanovsky and Szekely, 
1998). The most common reasons for the hypothermia which precedes fever are unfavourable 
experimental conditions during or after inflammatory insult such as an ill animal,  a low ambient 
temperature (below the animals thermoneutral zone (TNZ))  or a very strong inflammatory insult 
(Leon, 2004, Romanovsky et al., 2005). The TNZ for a rat lies between 27 – 30 °C (Leon, 2004, 
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Maloney et al., 2014, Romanovsky et al., 1996) and normal laboratory ambient temperatures 
generally range between  20 – 24 °C (Leon, 2004, Maloney et al., 2014).  Rodents are particularly 
vulnerable to an inflammatory insult when they are housed in an environment with an ambient 
temperature lower than their TNZ, this is due to their high surface area to body mass ratios (Leon, 
2004).  A study in which LPS (5 mg/kg) was administered peripherally to rats showed that if LPS 
was administered to rats at an ambient temperature within  their TNZ (28 °C) rats developed fever, 
however when the same dose of LPS was administered to rats at an ambient temperature below their 
TNZ (22 °C) it resulted in hypothermia (Liu et al., 2012). Both hypothermia and fever are the direct 
result of active thermogenic effectors within the brain and are achieved by an increase in heat gain 
or a decrease in heat loss mechanisms respectively  (Leon, 2004). After an inflammatory insult, heat 
production mechanisms compete with heat loss mechanisms to induce fever (Rudaya et al., 2005). 
However when infection occurs at a low ambient temperature, heat gain mechanisms become harder 
to activate and heat loss mechanisms are predominate, which results in the development of a 
moderate hypothermia, followed by a fever of low magnitude and a delayed onset (Rudaya et al., 
2005). For the duration of my study the ambient temperature in my laboratory ranged between 22 - 
23 °C. Furthermore, although the doses of LPS used in my study (10 and 100 µg) are low compared 
to the doses of LPS administered in simulated peripheral infections (0.5 – 10 mg/kg) (Leon, 2004, 
Romanovsky et al., 1996, Romanovsky and Szekely, 1998), the intra-cisterna magna doses I used 
are 1000 to 10000 fold higher than those used in other studies which simulated central infections 
using LPS (10 – 60 ng) (Ledeboer et al., 2002, McCarthy et al., 1986). Therefore, in light of the 
conditions under which my study was conducted (high doses of LPS administered at a low ambient 
temperature) this could explain the reason for the biphasic temperature response seen after the intra-
cisterna magna administration of LPS to rats in my study.  
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Both the peripheral and central administration of LPS induce the release and synthesis of multiple 
pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α (Conti et al., 2004, Leon, 2004) all of 
which are classified as endogenous pyrogens and are involved in febrigenesis (Cunningham et al., 
2005; Gabellec et al., 1995; Laye et al., 1994; Quan et al., 1998). However, TNF-α can also act as 
an endogenous cryogen and has been demonstrated to be the predominant mediator of hypothermia 
in both peripheral and central infections (Leon, 2004, Matsui et al., 2006, Romanovsky et al., 2005). 
The cyrogenic ability of TNF-α is demonstrated by several factors: (1) centrally administered TNF-
α has shown to induce hypothermia in rodents (Holt et al., 1989), (2) LPS induced TNF-α release 
correlates with hypothermic events (Blanque et al., 1996) and (3) TNF-antiserum has shown to 
attenuate LPS induced hypothermia (Derijk and Berkenbosch, 1994).  
Furthermore, a study in which LPS was administered peripherally to rats demonstrated that 
increased serum concentrations of TNF-α, which were associated with hypothermia, also played a 
role in mediating LPS-induced anorexia (Tollner et al., 2000). Clinically, hypothermia is associated 
with severe infections and patients that present with hypothermia are prone to organ failure and 
have a higher incidence of mortality than patients that present with fever (Clemmer et al., 1992, 
Marik and Zaloga, 2000). Therefore, because hypothermia is often associated with severe infections 
it may also be associated with an increase in inflammatory responses and so may produce 
exaggerated sickness responses.  
In contrast to the differences observed for body temperature between the intra-cisterna magna and 
the intracerebroventricular administration of LPS, my finding that the intra-cisterna magna injection 
of LPS induced lethargy and anorexia in rats has previously been shown in studies wherein LPS was 
administered intracerebroventricularly to rats and mice. Previous research has demonstrated that the 
intracerebroventricular administration of LPS (100 ng) potently induces lethargy in rats (Castanon et 
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al., 2001), my data are in line with this study and showed that the intra-cisterna magna 
administration of LPS (10 and 100 µg) dose-dependently induced lethargy which was maintained 
for up to 4 nights after injection (see Figure 3.2). In addition, I also confirmed the anorexigenic 
effects of  intracerebroventricularly administered LPS (3 ng – 2.5 µg) described in the literature 
(Bluthe et al., 1999, Bluthé et al., 2000, Burgess et al., 1998, Castanon et al., 2001, Faggioni et al., 
1995) by showing that the intra-cisterna magna administration of LPS (10 and 100 µg) to rats 
induced a dose-dependent decrease in both food intake and body mass (see Figure 3.3A and Figure 
3.3B respectively); body mass remained stunted for at least 4 days. Body mass stunting is a 
phenomenon which, to my knowledge, has not previously been demonstrated after the central 
administration of LPS. 
To assess memory in rats I chose to use the fear conditioning task because it has been used 
extensively in various laboratories to test for memory impairment in rodents (Avital et al., 2003, 
Barrientos et al., 2004, Goshen et al., 2007, Hein et al., 2007, Pugh et al., 1998, Terrando et al., 
2010). In addition, fear conditioning allows for the testing of two different types of memory, 
specifically hippocampal-dependent and amygdala-dependent memory, which enables a direct 
comparison between the two different types of memory. Furthermore, the fear conditioning task 
only requires one period of learning as opposed to other memory paradigms e.g. the Morris water 
maze which has several learning trials (Morris, 1981). Fear conditioning only requires the 
administration of a substance once (either before or after learning) however, because the Morris 
water maze has multiple learning trials it may require multiple administrations of a substance and 
because I chose to administer substances via the cisterna magna in my study, due to ethical 
considerations I could only inject my rats once.  
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Memory is a multi-stage process which includes: acquisition, consolidation, storage and finally 
retrieval of the stored memory (Abel and Lattal, 2001). In the context of the fear conditioning task; 
memory acquisition is the stage at which rats learn to make an association between the context, the 
tone and the foot shock experienced in the context chamber (Abel and Lattal, 2001). Memory 
consolidation occurs once the animal is returned to its home cage and can take place anywhere 
between a few minutes to 24 h (Barrientos et al., 2002), it is the process in which the early memory 
becomes cemented into a fixed state (Abel and Lattal, 2001). Once memory consolidation occurs the 
fixed memory is then stored in the hippocampus as a long-term memory (Abel and Lattal, 2001, 
Rudy et al., 2004). Memory retrieval occurs when the rat is returned to the context or auditory 
chamber for testing and the fear of the context; fear of the tone associations are tested respectively 
(Abel and Lattal, 2001). It can become complicated to isolate the different stages of memory, 
particularly when trying to determine which stage has been affected by a substance, this is because 
often more than one stage could potentially be effected. Therefore the timing of substance 
administration (either before or after conditioning/learning) is a very important factor to consider. If 
a substance is administered before conditioning/learning, it has the potential to effect memory 
acquisition (learning) and memory consolidation (Cunningham and Sanderson, 2008, Thomson and 
Sutherland, 2006). If a substance is administered after learning has taken place it has the ability to 
effect memory consolidation (Cunningham and Sanderson, 2008, Thomson and Sutherland, 2006).  
When a substance is administered before learning takes place it may result in an abnormal sensory 
experience during learning (Rudy et al., 2004). During fear conditioning, memory acquisition relies 
on the formation of a contextual representation which involves binding together the individual 
features of the context to form a unified neural ensemble (Rudy et al., 2004). However if the rat has 
an abnormal sensory experience in the context chamber it will form an inadequate or incomplete 
contextual representation (Rudy et al., 2004), which will result in memory impairment. However 
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impairment of memory acquisition is not necessarily due to a loss in memory function but is rather 
due to a performance deficit in forming a contextual representation  (Rudy et al., 2004). 
Furthermore, when a substance is administered either before or after learning takes place it has the 
potential to effect memory consolidation. Due to the variability in the period during which memory 
consolidation occurs it is the stage of memory formation most vulnerable to disruption (Abel and 
Lattal, 2001). Memory consolidation is hypothesized to rely predominantly on neural plasticity 
initiated in the hippocampus (Goshen and Yirmiya, 2006, Huang and Sheng, 2010, Yirmiya and 
Goshen, 2011), which involves the formation, degradation and change of neural pathways and 
synapses (Yirmiya and Goshen, 2011). The most important type of neural plasticity involved in 
memory consolidation is long-term potentiation (LTP) (Goshen and Yirmiya, 2006, Huang and 
Sheng, 2010, Yirmiya and Goshen, 2011), which is a persistent increase in synaptic efficacy 
following high frequency stimulation of a synapse, it results in long-lasting signal transmission 
between two neurons (Huang and Sheng, 2010). The administration of an intervention either before 
or after learning has the ability to impair neural plasticity and LTP, thereby impairing memory 
consolidation (Goshen and Yirmiya, 2006; Huang and Sheng, 2010; Pugh et al., 2001; Yirmiya and 
Goshen, 2011). Once memory consolidation is impaired the contextual representation formed during 
acquisition is no longer available, resulting in weak fear conditioning which will manifest itself as a  
decrease in freezing during the context test (Rudy et al., 2004). 
Interestingly despite the strong link between LPS and central infections (E. coli has been shown to 
induce bacterial meningitis and brain abscesses), my study was the first to examine the effect of 
centrally administered LPS on hippocampal-dependent memory using fear conditioning. My results 
showed that during conditioning all of the groups were active and explored the chamber 
approximately 95 – 100 % of the time (see Figure 3.4A) which indicates that none of the rats were 
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sick or lethargic during conditioning (Barrientos et al., 2012). Although rats assigned to receive 100 
µg of LPS froze significantly more during conditioning than the other groups the difference was 
small and may be attributed to the small sample size and high inter-individual variability however, it 
is not considered to be biologically significant. Similarly the elevated freezing during the pre-tone 
period for rats that received 100 µg of LPS does not indicate that rats were sick or lethargic as all 
the sickness responses had resolved prior to memory testing, the difference is also likely due to the 
small sample size and high inter-individual variability. Contrary to what I expected based on the 
findings from peripheral LPS studies (Pugh et al., 1998, Terrando et al., 2010) and despite the 
potent effect that the intra-cisterna magna injection of LPS had on body temperature, activity, food  
intake and body mass; LPS had no effect on hippocampal-dependent memory in my study, 
regardless of the dose administered (see Figure 3.4B). Thus these findings collectively indicate that 
there appears to be a dissociation between memory impairment and the other sickness responses.  
The possible reasons as to why I did not see memory impairment in my study are several fold. 
Firstly it may be related to the doses of LPS used (10 and 100 µg), previously a study examined the 
dose-effect of peripherally administered LPS on memory in rats and determined that the low (0.5 
mg/kg) and high dose (2 mg/kg) of LPS had no effect on either hippocampal or amygdala-
dependent memory, however the moderate dose (1 mg/kg) caused hippocampal-dependent memory 
impairment (Pugh et al., 1998), therefore peripherally administered LPS appears to act on memory 
in an U-shaped dose response curve (Pugh et al., 1998). Hence it is possible centrally administered 
LPS also acts on memory in a U-shaped dose-response curve and therefore the two doses of LPS I 
administered to my rats may have been too high, in terms of a central infection, to cause memory 
impairment. In order to verify whether centrally administered LPS acts on memory in a U-shaped 
dose-response curve, similarly to peripherally administered LPS (Pugh et al., 1998), it would be 
useful to administer several doses of LPS via the cisterna magna and examine their effects on 
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memory using fear conditioning. Secondly, because memory consolidation may occur within a 
highly variable period of time (Abel and Lattal, 2001, Barrientos et al., 2002, Rudy et al., 2004) and 
even though LPS may have induced an increase in cytokine concentrations within the brain for a 
protracted period of time, in my study the onset of cytokine elevation may have occurred after 
memory consolidation had taken place. Thirdly, key proteins known to impair memory 
consolidation, such as IL-1β, may not have been raised enough at the point at which memory 
consolidation occurred.  
Although I did not measure cytokine concentrations in the brain after I administered LPS via the 
cisterna magna to rats; previous research in which LPS was administered peripherally to rats 
showed that there is a  relationship between fever and hypothermia with serum and brain 
concentrations of TNF-α and IL-1β (Blanque et al., 1996, Deak et al., 2005, Skelly et al., 2013). 
Following a peripheral LPS injection TNF-α serum concentrations increased with the onset of 
hypothermia and decreased rapidly whereas there was a delayed onset of serum IL-1β elevation 
(Blanque et al., 1996). In addition, a study in which peripherally administered LPS resulted in 
hypothermia in mice showed that 2 h after the administration of LPS there was greater hypothalamic 
mRNA transcription of TNF-α compared to hypothalamic mRNA transcription of IL-1β (Skelly et 
al., 2013). Furthermore a study in which the peripheral administration of LPS  induced a fever 
showed that brain IL-1β concentrations remained elevated in the brain for a similar period of time  
that body temperature remained elevated after LPS injection (Deak et al., 2005). Therefore I can 
speculate in relation to the abdominal temperature data obtained for the rats that received LPS in my 
study (see Figure 3.1) that brain TNF-α concentrations were originally elevated with the onset of 
hypothermia at approximately 1-2 h after LPS injection; followed by a delayed increase in IL-1β at 
approximately 4 h following administration of the low dose (10 µg) of LPS and 18 h for the high 
dose (100 µg) of LPS.  TNF-α  has not been shown to play a consistent role in memory impairment 
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(Goshen and Yirmiya, 2006) and based upon my speculation if TNF-α was raised at the point which 
memory consolidation took place, it may be the reason that I did not see memory impairment in my 
study following the intra-cisterna magna administration of LPS to rats.  In order to verify this 
speculation it is important to measure brain TNF-α and IL-1β concentrations at several time points 
following the intra-cisterna magna injection of LPS.  
4.2. Interleukin-1β induced sickness responses 
 
Numerous studies have determined that the peripheral and central administration of LPS results in 
the de novo synthesis and release of a host of pro-inflammatory cytokines (e.g. IL-1α, IL-1β, IL-6, 
IL-8 and TNF-α) in the brain which work additively and synergistically in order to induce sickness 
responses (Conti et al., 2004, Leon, 2004). The three pro-inflammatory cytokines predominantly 
associated with LPS-induced sickness responses are IL-1β, IL-6 and TNF-α (Conti et al., 2004, 
Skelly et al., 2013). Although it would have been preferable to examine and compare the effects of 
all of the three major cytokines implicated in LPS-induced sickness responses, based on time 
constraints I chose one – namely IL-1β.  
I chose to administer IL-1β instead of IL-6 and TNF-α because the intracerebroventricular 
administration of IL-1β consistently induces fever (Anforth et al., 1998, Harden et al., 2008), 
anorexia (Plata-Salamán, 1994) and lethargy (Harden et al., 2008, Plata-Salamán, 1994), whereas 
the intracerebroventicular administration of IL-6 consistently induces fever (Harden et al., 2008) but 
not other sickness behaviours such as anorexia (Harden et al., 2008). In addition although the 
intracerebroventicular administration of TNF-α consistently induces anorexia, depending on the 
dose of TNF-α (Plata-Salamán et al., 1988) it may either induce hypothermia or a fever (Leon, 
2004). Moreover, studies which examined the relative potency of IL-1β, IL-6 and TNF-α by 
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comparing the magnitude of sickness responses induced by the individual cytokines administered at 
the same dose determined that in central infections IL-1β is the most potent inducer of fever, 
lethargy and anorexia (Harden et al., 2008, Sonti et al., 1996). Furthermore, IL-1β is also the pro-
inflammatory cytokine that has been implicated most often in neurodegenerative diseases, as well as 
memory impairment associated with central infections (Cunningham et al., 2005, Goshen and 
Yirmiya, 2006, Rothwell and Luheshi, 2000), whereas the central administration of IL-6 and TNF-α 
have not consistently been shown to have an effect on memory (Goshen and Yirmiya, 2006).  
Although I am the first researcher to my knowledge to have examined the effects of IL-1β (100 ng) 
administered via the cisterna magna on body temperature in rats, my findings are in line with 
previous research which demonstrated the pyrogenic properties of intracerebroventricularly 
administered IL-1β to rodents (Anforth et al., 1998, Busbridge et al., 1989, Cao et al., 2001, Harden 
et al., 2008, Kent et al., 1992, Li et al., 2001, Montkowski et al., 1997, Oitzl et al., 1993). I 
demonstrated that IL-1β administered via the cisterna magna is potently pyrogenic and resulted in 
the development of a fever which lasted for up to 48 h (see Figure 3.5). Furthermore, I demonstrated 
that the intra-cisterna magna administration of IL-1β (100 ng) to rats resulted in lethargy which was 
maintained for up to 2 nights after injection (see Figure 3.6) as well as a decrease in food intake and 
body mass, which are indicators of anorexia, and which were maintained for 2 and 3 days after 
injection respectively (see Figure 3.7). My findings that IL-1β is a potent promoter of lethargy and 
anorexia further confirmed and supported the results in the literature which have shown that 
intracerebroventricularly administered IL-1β causes a decrease in activity (Bluthé et al., 2000, 
Montkowski et al., 1997, Plata-Salamán, 1994), food intake and body mass (Bluthé et al., 1995, 
Bluthé et al., 2000, Harden et al., 2008, Kent et al., 1992, Kent et al., 1994, Montkowski et al., 
1997, Sonti et al., 1996). Collectively, central IL-1β appears to be a potent mediator of sickness 
responses, regardless of the route by which it is administered centrally. 
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In order to assess memory rats were assigned to receive IL-1β (100 ng) either 2 h before 
conditioning or immediately after conditioning, they were then tested for fear of the context and fear 
of the tone 7 days later. Rats that received IL-1β (100 ng) immediately after conditioning (learning) 
were not under the influence of IL-1β during conditioning; hence my results showed that these rats 
explored the context chamber with equal interest to rats that received BSA and froze for ~ 1 % (see 
Figure 3.8A). Although the relationship between IL-1β and memory is complex, the literature 
suggests that centrally administered IL-1β (either via the third cerebral ventricle or via the 
hippocampus), immediately after conditioning, is consistently either beneficial or deleterious to 
hippocampal-dependent memory (Barrientos et al., 2002, Barrientos et al., 2004, Goshen et al., 
2007, Hein et al., 2007, Pugh et al., 1999). Interestingly my study showed that the intra-cisterna 
magna administration of 100 ng of IL-1β immediately after conditioning had no impact on 
hippocampal-dependent memory (see Figure 3.9 B). Similar findings for memory function have not 
previously been reported when using the fear conditioning task which is surprising because IL-1β 
has been hypothesized to act on memory in an inverted U-shaped pattern which suggests that basal 
levels of IL-1β in the brain are necessary for memory formation to take place but any deviation 
either by causing over or under expression of IL-1β will be detrimental to memory consolidation 
(Goshen et al., 2007, Goshen and Yirmiya, 2006). My results further add to the complexity of the 
relationship between IL-1β and memory and may be due to several reasons. Firstly a study which 
peripherally administered LPS to rats determined that LPS acted on hippocampal-dependent 
memory in a U-shaped dose response, that is to say that a mid range dose of LPS caused 
hippocampal-dependent memory impairment but a low and high dose of LPS had no effect on 
memory (Pugh et al., 1998)., therefore it is a possibility that IL-1β may also act in a U-shaped dose-
response on memory. As evidence for the potential U-shaped dose-response of IL-1β on memory, 
studies which centrally administered (via the third cerebral ventricle or via the hippocampus) 10 ng 
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of IL-1β to rodents have consistently demonstrated that IL-1β causes memory impairment at this 
dose (Barrientos et al., 2004, Goshen et al., 2007, Hein et al., 2007, Pugh et al., 1999). However, 
the dose I administered to rats (100 ng) is 10 times greater than that used in previous studies and 
showed no memory impairment. Furthermore a study in which peripherally administered E. coli 
caused hippocampal-dependent memory impairment in the fear conditioning task showed that 
hippocampal IL-1β levels were raised to 1 x 10-5 pg/mg and 1.2 x 10-5 pg/mg at 2 and 4 h after 
injection respectively (Barrientos et al., 2009) whereas after the central administration of IL-1β I 
obtained IL-1β concentrations of 15 pg/mg and 22 pg/mg at 2 and 4 h after IL-1β injection in the 
hippocampus respectively. In order to determine if IL-1β does act on memory in a U-shaped dose-
response it is important to test the effect that several doses of IL-1β have on hippocampal-dependent 
memory. Secondly, all of the studies which showed hippocampal-dependent memory impairment 
administered IL-1β intracerebroventricularly or intrahippocampally (Barrientos et al., 2004, Goshen 
et al., 2007, Hein et al., 2007, Pugh et al., 1999), whereas I administered IL-1β via the cisterna 
magna. A study in which the tracer inulin was injected into the cisterna magna or the third cerebral 
ventricle of rats noted that there were subtle differences in the early distribution of the tracer within 
the brain depending on the site of injection (Proescholdt et al., 2000), therefore it may be possible 
that the different routes of injection affect memory differently. In order to determine if there is a 
difference between the effect each route has on memory, injections via the cisterna magna, third 
cerebral ventricle and hippocampus should be compared using the same dose of IL-1β.  
My results showed that rats that received 100 ng of IL-1β 2 h before they were conditioned froze 
more during conditioning (learning) than rats that received IL-1β immediately after conditioning 
and rats that received BSA (see Figure 3.8A). Rats that received IL-1β 2 h before being conditioned 
froze approximately 13 % of the time they were in the context chamber, in addition they were 
febrile (see Figure 3.5) and had elevated brain IL-1β concentrations (see Figure 3.9) during 
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conditioning (learning), therefore the increased freezing time during conditioning may be indicative 
that rats were also lethargic. Furthermore, rats that were conditioned 2 h after receiving IL-1β 
showed both hippocampal and amygdala-dependent memory impairment (see Figure 3.8 B and C 
respectively).    
Rats that received IL-1β 2 hours before being conditioned were febrile and had elevated brain IL-1β 
concentrations during conditioning and for several hours afterward (~ 8 h) therefore rats were under 
the influence of IL-1β during and after learning which gives an indication that IL-1β may have 
affected either memory acquisition or memory consolidation. During memory acquisition rats were 
under the influence of IL-1β which may have resulted in an abnormal sensory experience during 
conditioning (learning) and therefore may have caused the formation of an incomplete contextual 
representation (Rudy et al., 2004) which will have resulted in both hippocampal and amygdala-
dependent memory loss. In order to verify if memory acquisition was indeed affected it would be 
useful to test memory retention for the context and the tone before memory consolidation has taken 
place ~ 1 h after conditioning (Barrientos et al., 2006) and if rats show memory impairment it can 
be confirmed that IL-1β administered 2 h before conditioning affected memory acquisition. Memory 
consolidation occurs in the hippocampal formation and the central administration of IL-1β has 
consistently been demonstrated to impair hippocampal-dependent memory through the impairment 
of LTP and neural plasticity (Goshen and Yirmiya, 2006, Huang and Sheng, 2010, Yirmiya and 
Goshen, 2011). If damage occurs to the hippocampus after the administration of a substance it will 
result in impaired hippocampal-dependent memory whereas amygdala dependent memory remains 
intact and unaffected (Phelps, 2004, Rudy et al., 2004, Sanders et al., 2003). Throughout the 
literature when memory consolidation is affected by IL-1β; memory impairment in the fear 
conditioning task is limited to hippocampal-dependent memory (Barrientos et al., 2002, Barrientos 
et al., 2004, Pugh et al., 1998, Pugh et al., 1999). However, I showed that the administration of IL-
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1β 2 h before conditioning impaired both hippocampal and amygdala-dependent memory, therefore 
my results are inconsistent with the literature and consequently it is unlikely that memory 
consolidation was affected in my study.  
4.2.1. Brain IL-1β concentrations 
 
In view of the lack of information regarding sickness responses following the intra-cisterna magna 
injection of IL-1β I set out to further investigate these relationships by measuring the concentration 
of IL-1β in the hippocampus and hypothalamus at several time points after intra-cisterna magna 
injection of IL-1β. I chose to investigate the concentrations of IL-1β in the hypothalamus because 
the thermoregulatory centre of the brain is hypothesized to be located in the pre-optic nucleus of the 
hypothalamus (Conti et al., 2004) moreover, the hypothalamus is also hypothesized to be the 
primary site for regulation of feeding (Plata-Salamán, 1998). Furthermore, I chose to investigate the 
concentration of IL-1β in the hippocampus because the hippocampus is the predominant brain 
structure involved in declarative or hippocampal-dependent memory (Phelps, 2004). 
Although not significantly different across time points, BSA induced the presence of IL-1β in both 
the hippocampus and the hypothalamus (see Figure 3.9), this is not surprising as it has been reported 
that BSA can induce an inflammatory response when administered to rats (Jankovic et al., 1962). 
Compared to rats that received BSA, rats that received IL-1β (100 ng) had significantly elevated IL-
1β concentrations at 1, 4 and 8 h after injection in both the hypothalamus and the hippocampus (see 
Figure 3.9). Anomalously, at 2 h hippocampal and hypothalamic IL-1β concentrations were similar 
for rats that received either IL-1β or BSA, which most likely is due to a small sample size of rats 
that received BSA as well as high inter-individual variability. Nonetheless, there was sustained 
elevation in IL-1β concentrations (in both the hypothalamus (15 – 28 pg/mg) and hippocampus (15-
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24 pg/mg)) from 1 - 8 h after injection within the group of rats that received IL-1β. The elevated 
concentrations of IL-1β in the hypothalamus at 1 h corresponded to the onset of the febrile response, 
moreover the return of IL-1β concentrations to baseline at 24 h corresponded to the resolution of 
fever which collectively gives an indication that IL-1β plays a role in the mediation of fever.  In 
addition, by 24 h after injection rats were lethargic and showing signs of anorexia (decrease in food 
intake and body mass) which gives an indication that IL-1β may play a role in the initiation of 
lethargy and anorexia. Moreover, rats that received IL-1β 2 h before conditioning had elevated 
levels of IL-1β in the hippocampus during learning which resulted in memory impairment. 
Therefore, it appears that if learning occurs during a time in which IL-1β is elevated within the brain 
(~ 15 pg/mg) it could result in memory impairment.  
4.3. Future studies 
 
In order to further complete my current study it would be useful to examine the effect of several 
doses of LPS administered via the cisterna magna on memory (and the other sickness responses) in 
order to confirm whether centrally administered LPS exerts its effect on hippocampal-dependent 
memory in a U-shaped dose response, similarly to the U-shaped dose response seen with 
peripherally administered LPS (Pugh et al., 1998). Moreover, it would be useful to map out the 
expression of hypothalamic and hippocampal pro-inflammatory cytokines IL-1β and TNF-α 
concentration at several time points following the intra-cisterna magna administration of LPS in 
order to investigate the role of these cytokines in LPS-induced hypothermia and fever, as well as to 
explore why LPS did not induce memory impairment in my study.   
My results have demonstrated that memory impairment may appear in conjunction with other 
sicknesses responses if learning occurs when IL-1β is elevated in the brain. However, because IL-1β 
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was administered to rats 2 h before conditioning IL-1β may have affected either memory acquisition 
or memory consolidation. In order to determine whether memory acquisition was effected following 
administration of IL-1β, 2 h before conditioning, fear of the context should be tested ~ 1 h after 
conditioning, before memory consolidation has taken place. Moreover, the dose of IL-1β (100 ng)  
administered in my study has not previously been studied for its effect on memory, if IL-1β acts on 
memory in a U-shaped dose response 100 ng of IL-1β may have been too high to affect memory. 
Therefore it would be interesting to conduct a dose response study using IL-1β administered via the 
cisterna magna at doses previously seen to effect memory when administered via the third cerebral 
ventricle (e.g. 1 ng, 2 ng and 10 ng). In addition, the effect of IL-1β administered via the cisterna 
magna has not previously been examined for its effect on memory. There are differences between 
the early distribution of substances within the brain when administered via the cisterna magna and 
third cerebral ventricle (Proescholdt et al., 2000); consequently there may be differences between 
the routes for their effect on memory.  Therefore it would be of interest to compare the effect of one 
dose of IL-1β, administered via the cisterna magna and the third cerebral ventricle, on memory. My 
study could also potentially be replicated using a human model of infection by peripherally 
administering LPS and/or IL-1β to adults at different time points, either before or after a learning 
task has taken place. The human study would give some insight as to whether the results seen in my 
study are limited to animal models of infection or whether they may apply to humans as well.  
Finally, infection and inflammation are not caused by the isolated increase of one pro-inflammatory 
cytokine but rather through the collective action of a pro-inflammatory network which includes 
multiple pro-inflammatory cytokines (e.g. IL-1, IL-6, IL-8, TNF-α) and other downstream  
mediators (e.g. PGE2, Interferons) (Donzis and Tronson, 2014). Similarly when IL-1β is 
administered exogenously to rats it does not act on the brain alone, it exerts its effects on the brain 
both directly and indirectly via signaling of the pro-inflammatory network (Donzis and Tronson, 
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2014). Therefore many of the effects caused by the exogenous administration of IL-1β are due to the 
cumulative effect of many pro-inflammatory cytokines  (Donzis and Tronson, 2014). Consequently, 
given the complexity of the relationship between IL-1β and memory, shifting focus from the 
individual effects of pro-inflammatory cytokines on memory to the effect of the whole pro-
inflammatory cascade on memory by using live organisms or moieties may be more constructive in 
understanding the impact of immune activation on memory (Donzis and Tronson, 2014).  
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Chapter 5  
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My results suggest that a simulated, acute central infection in rats severe enough to induce a host of 
sickness responses including fever, anorexia and lethargy may occur without incurring any negative 
cognitive sequelae. The dissociation between memory impairment and other sickness responses in 
my study parallels emerging evidence in other rodent models of infection that peripherally 
administered IL-1β (Thomson and Sutherland, 2006) and fibroblast-stimulating lipopeptide-1, the 
moiety of Mycoplasma salivarium (Swanepoel et al., 2011), can induce fever, anorexia and lethargy 
in the absence of memory impairment. However, as demonstrated by my study the timing of 
learning relative to inflammation within the brain is very important. If learning occurs during a time 
at which there is inflammation in the brain and/or when the host is exhibiting signs of sickness such 
as fever and lethargy it may result in memory impairment.  
No direct extrapolation of the outcome of my study can be made to humans, moreover the results 
from my study cannot be extrapolated to all central infections. Cognitive damage as a result of 
central bacterial infections is dually mediated by centrally released pro-inflammatory cytokines and 
by the direct toxicity of bacterial components on the brain (Nau and Bruck, 2002, Weber and 
Tuomanen, 2007). Experimental models of bacterial meningitis using live organisms (E. coli, 
Streptococcus pneumoniae, Klebsiella pneumoniae)  have consistently been demonstrated to cause 
cognitive deficits in rats (Barichello et al., 2014a, Barichello et al., 2013, Barichello et al., 2010, 
Barichello et al., 2014b). As confirmation of the dual mediation of cognitive damage, experimental 
models of bacterial meningitis in rats have demonstrated that live bacterial organisms result in the 
expression of pro-inflammatory cytokines throughout the brain including the hippocampus 
(Barichello et al., 2013) and furthermore that bacterial toxicity results in neuronal apoptosis in the 
hippocampus (Braun et al., 1999). Both, the expression of pro-inflammatory cytokines and bacterial 
toxins have previously been associated with impaired learning and cognitive dysfunction (Loeffler 
et al., 2001). Interestingly, although experimental models of LPS infection have determined that 
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LPS is associated with cognitive dysfunction (Pugh et al., 1998), as well as the expression of pro-
inflammatory cytokines in the brain (Conti et al., 2004), in vitro studies examining the toxicity of 
LPS have determined that LPS is free of the prototypical bacterial toxins which may cause cognitive 
impairments in central infections (Weber and Tuomanen, 2007). Therefore, although I simulated a 
central model of infection using both LPS and IL-1β my results cannot be extrapolated to other 
central bacterial infections because even though LPS and IL-1β both cause the release and synthesis 
of pro-inflammatory cytokines in the brain they are free from the prototypical bacterial toxins 
associated with other central bacterial infections.  
In conclusion despite having a severe central infection, memory impairment is not a ubiquitous 
sickness response and may only occur in conjunction with fever, anorexia and lethargy when 
learning occurs during an immune reaction within the brain.   
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